<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="HR" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-141-150</article-id>
<article-id pub-id-type="doi">10.26800/LV-141-5-6-21</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group>
</article-categories>
<title-group>
<article-title>Klini&#x010D;ka slika kasne novoro&#x0111;ena&#x010D;ke sepse &#x2013; i dalje ozbiljan diferencijalnodijagnosti&#x010D;ki problem</article-title>
<trans-title-group xml:lang="en">
<trans-title>Clinical manifestation of late neonatal sepsis &#x2013; continuous differential diagnostic dilemma</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Katavi&#x0107;</surname><given-names>Matej</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dasovi&#x0107; Buljevi&#x0107;</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<aff id="aff1"><label>1</label>Klinika za pedijatriju, KBC Sestre milosrdnice</aff>
<aff id="aff2"><label>2</label>Zavod za neonatologiju i neonatalno intenzivno lije&#x010D;enje, Klinika za pedijatriju, Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu, KBC Zagreb</aff>
</contrib-group>
<author-notes><corresp id="cor1">Adresa za dopisivanje: Matej Katavi&#x0107;, dr. med., Klinika za pedijatriju, KBC Sestre milosrdnice, Vinogradska cesta 29, 10000 Zagreb; e-mail: <email xlink:href="katavicmatej@gmail.com">katavicmatej@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>06</month><year>2019</year></pub-date>
<volume>141</volume>
<issue>5-6</issue>
<fpage>150</fpage>
<lpage>161</lpage>
<permissions>
<copyright-year>2019</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<p>SA&#x017D;ETAK. Novoro&#x0111;ena&#x010D;ka sepsa kao klini&#x010D;ki sindrom jedan je od naj&#x010D;e&#x0161;&#x0107;ih dijagnosti&#x010D;ko-terapijskih izazova u novoro&#x0111;ena&#x010D;koj dobi s relativno visokom stopom smrtnosti. Prema dobi manifestacije, dijeli se na ranu i kasnu sepsu, ovisno o izvorima i mi&#x0161;ljenjima raznih stru&#x010D;njaka. Mo&#x017E;e se o&#x010D;itovati poreme&#x0107;ajem svih organskih sustava i brojnim kasnim komplikacijama te znatnim morbiditetom i mortalitetom. Razdoblje od drugog tjedna &#x017E;ivota primarni je interes ovog rada jer je u tom periodu (dotad prividno zdrava) novoro&#x0111;en&#x010D;ad otpu&#x0161;tena ku&#x0107;i iz rodili&#x0161;ta, adaptirana na svakodnevne zahtjeve ekstrauterinog &#x017E;ivota, s mogu&#x0107;no&#x0161;&#x0107;u razvoja niza neinfektivnih stanja i bolesti koji klini&#x010D;ki izgledaju kao septi&#x010D;ko stanje. &#x0160;iroka diferencijalna dijagnoza takvog stanja mo&#x017E;e biti ozbiljan problem koji nala&#x017E;e hitnu reakciju, pravilno i pravodobno lije&#x010D;enje te, naposljetku, zbrinjavanje u adekvatnoj ustanovi ovisno o osnovnoj bolesti. Cilj je ovog pregleda upozoriti na niz neinfektivnih stanja koja se mogu prezentirati klini&#x010D;kom slikom kasne novoro&#x0111;ena&#x010D;ke sepse.</p>
</abstract>
<trans-abstract xml:lang="en">
<p>SUMMARY. Neonatal sepsis as a clinical syndrome is one of the most common challenges in neonatal medicine with a relatively high mortality rate. At the time of clinical manifestation it can be distinguished into early onset and late onset sepsis, highly depending on sources and medical experts opinions.Its multiorgan affection can be associated with major complications and high late morbidity and mortality. The period of the second week of life is the primary interest of this paper, because children who were thought to be healthy are discharged home from the maternity ward, more or less successfully adapted to extrauterine life with the possibility of developing serial noninfectious conditions and diseases that clinically impress as sepsis. Such state can make serious differental diagnostic difficulty and requires quick reaction with timely and appropriate therapy that could be crucial in the management of these patients. Definitive care should be continued in an adequate institution, depending on diagnosis. The aim of this review is pointing out the wide range of noninfectious conditions that can present as late onset neonatal sepsis.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori NOVORO&#x0110;ENA&#x010C;KA SEPSA &#x2013; dijagnoza, etiologija, lije&#x010D;enje</kwd><kwd>SEPTI&#x010C;KI &#x0160;OK &#x2013; dijagnoza, lije&#x010D;enje</kwd><kwd>DIFERENCIJALNA DIJAGNOZA</kwd><kwd>NOVORO&#x0110;ENA&#x010C;KE BOLESTI &#x2013; dijagnoza, lije&#x010D;enje</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>NEONATAL SEPSIS &#x2013; diagnosis, etiology, therapy</kwd><kwd>DIAGNOSIS, DIFFERENTIAL</kwd><kwd>SHOCK, SEPTIC &#x2013; diagnosis, therapy</kwd><kwd>INFANT, NEWBORN, DISEASES &#x2013; diagnosis, therapy</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Kasna novoro&#x0111;ena&#x010D;ka sepsa kao klini&#x010D;ki entitet i stanja koja se doimaju kao kasna novoro&#x0111;ena&#x010D;ka sepsa oduvijek su diferencijalnodijagnosti&#x010D;ki i terapijski izazov neonatolozima i pedijatrima. Zasad nema sustavnih pregleda koji ujedinjuju dijagnosti&#x010D;ko-terapijski protokol, no aktualno ispisani prikaz mogao bi biti poticaj pedijatrijskim i neonatolo&#x0161;kim dru&#x0161;tvima da zajedni&#x010D;kim snagama donesu preporuke o zbrinjavanju bolesnika koji se prezentiraju klini&#x010D;kom slikom kasne novoro&#x0111;ena&#x010D;ke sepse. Podaci u ovom tekstu preuzeti su iz brojnih neonatolo&#x0161;kih, pedijatrijskih i infektolo&#x0161;kih ud&#x017E;benika, zatim pretra&#x017E;ivanjem <italic>PubMeda</italic>, <italic>UpToDatea</italic>, <italic>Medscapea</italic> i ostalih medicinski va&#x017E;nih baza podataka te raznih smjernica, preporuka i preglednih radova. Dodatan kriti&#x010D;ki osvrt na cjelokupnu problematiku rezultirao je spajanjem svih podataka u slo&#x017E;enu cjelinu. Zaklju&#x010D;no, ovaj bi prikaz za specijalizante i specijaliste pedijatrije i neonatologije mogao biti dobar podsjetnik na &#x0161;iroku lepezu bolesti i stanja, a radi kvalitetnijeg lije&#x010D;enja i zbrinjavanja vitalno ugro&#x017E;ene novoro&#x0111;en&#x010D;adi.</p>
<sec sec-type="other1">
<title>Novoro&#x0111;ena&#x010D;ka sepsa</title>
<p>U&#x010D;estalost novoro&#x0111;ena&#x010D;ke sepse procjenjuje se na 0,5 do 8 na 1000 &#x017E;ivoro&#x0111;ene djece. Prema po&#x010D;etku javljanja, dijeli se na vrlo ranu sepsu, koja se o&#x010D;ituje ve&#x0107; pri ro&#x0111;enju, u prvim satima, odnosno do 24 sata postnatalno, zatim na ranu sepsu, s javljanjem u prva tri, pet odnosno sedam dana, ovisno o izvorima te na kasnu sepsu (do 28. dana), tj. prema nekim autorima, vrlo kasnu sepsu (do 90. dana). &#x010C;e&#x0161;&#x0107;e se javlja u nedono&#x0161;&#x010D;adi (10 &#x2013; 30/1000), mu&#x0161;ke djece (s incidencijom ve&#x0107;om i do &#x0161;est puta), a sama incidencija i prevalencija te mortalitet i morbiditet obrnuto su proporcionalni gestacijskoj dobi. Uzro&#x010D;nici rane sepse prenose se vertikalno s majke na plod, dok prijenos uzro&#x010D;nika kasne sepse mo&#x017E;e biti vertikalan ili horizontalan i manifestira se septikemijom s razvojem meningitisa ili bez njega.</p>
<p>Kasna sepsa naj&#x010D;e&#x0161;&#x0107;e je uzrokovana bakterijama kao &#x0161;to su <italic>Streptococcus</italic> grupe B (BHS-B), <italic>E. coli</italic>, <italic>Enterobacter</italic>, <italic>L. monocytogenes</italic>, <italic>S. aureus</italic>, <italic>K. pneumoniae</italic>, koagulaza-negativan <italic>Staphylococcus</italic>, <italic>P. aeruginosa</italic>, <italic>Acinetobacter</italic>, <italic>Serratia</italic> te anaerobi. Mogu&#x0107;a je i infekcija virusima i uzro&#x010D;nicima gljivnih infekcija, ponajprije <italic>Candidom albicans</italic> (<xref ref-type="table" rid="t1">Table 1</xref>).</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Most common causative agents of LOS (modified after ref <xref ref-type="bibr" rid="r13">13</xref> and <xref ref-type="bibr" rid="r1">1</xref>-<xref ref-type="bibr" rid="r20">20</xref> and <xref ref-type="bibr" rid="r25">25</xref> combined)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="100%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x00A0;&#x00A0;Bakterije/Bacteria<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;BHS-B (&#x03B2;-hemoliti&#x010D;ki streptokok grupe B)/<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;BHS-B (&#x03B2;-haemolytic streptococcus group B)<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Escherichia coli</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Staphylococcus aureus</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Enterobacteriaceae</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Listeria monocytogenes</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Klebsiella pneumoniae</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>koagulaza-negativan stafilokok (KNS)/coagulase negative staphylococcus (CNS)</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Pseudomonas aeruginosa</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Streptococcus pneumoniae</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Haemophilus influenzae</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Neisseria meningitidis</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Neisseria gonorrhoeae</italic><break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Salmonella</italic> spp.<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;<italic>Enterococcus</italic> spp.</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x00A0;&#x00A0;Virusi/Viruses<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;HSV<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CMV<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Enterovirusi/Enteroviruses &#x2013; Coxsackie B<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Adenovirusi/Adenoviruses<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;RSV<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Influenca/Influenza virus</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">&#x00A0;&#x00A0;Gljive/Fungi &#x2013; <italic>Candida</italic> spp.</td>
</tr>
</tbody></table></table-wrap>
<p>Faktori rizika od nastanka sepse jesu infekcije ko&#x017E;e djeteta ili pup&#x010D;ane rane, infekcija mokra&#x0107;nog sustava, aspiracija mlijeka, aspiracija povra&#x0107;enog ili drugog sadr&#x017E;aja, infekcija ko&#x017E;e na maj&#x010D;inim bradavicama, maj&#x010D;ina aktivna bolest ili bolesni &#x010D;lanovi obitelji, lo&#x0161; socioekonomski status obitelji i nepa&#x017E;ljivo pona&#x0161;anje posjetitelja u domu. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Uz navedeno, novoro&#x0111;en&#x010D;e je dodatno osjetljivo za infekcije zbog nezrelog imunosnog sustava, osobito nespecifi&#x010D;ne imunosti, posebno kod infekcija <italic>E. coli</italic> i BHS-B-om te sustava fagocitoze (izra&#x017E;enog kod infekcije gram-negativnim bakterijama). (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r4"><italic>4</italic></xref>, <xref ref-type="bibr" rid="r21"><italic>21</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>, <xref ref-type="bibr" rid="r25"><italic>25</italic></xref>, <xref ref-type="bibr" rid="r26"><italic>26</italic></xref>)</p>
<p>Bolest se o&#x010D;ituje u rasponu od blagih i nespecifi&#x010D;nih znakova do stanja septi&#x010D;kog &#x0161;oka. To su ponajprije letargija, oslabljeno sisanje, odbijanje hrane, hipotonus/hipertonus, slab ili visokofrekventan pla&#x010D;, termonestabilnost (tjelesna temperatura &lt; 36 &#x00B0;C ili &gt; 37,9 &#x00B0;C), tahikardija, produljeno vrijeme kapilarnog punjenja, promjena boje ko&#x017E;e (bljedilo ili cijanoza), tahipneja. Poslije su mogu&#x0107;i i bradipneja s povremenim ili stalnim apnejama te stenjanje, uporaba pomo&#x0107;ne respiratorne muskulature i/ili desaturacija krvi kisikom, intolerancija glukoze (glukoza u krvi &gt; 10 mmol/L) ili hipoglikemija. Klasi&#x010D;ni meningiti&#x010D;ki znakovi u toj dobi obvezatno izostaju. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>)</p>
<p>Za potvrdu dijagnoze potrebna je ograni&#x010D;ena laboratorijska obrada (CRP, PCT, KKS s diferencijalnom krvnom slikom, pretraga urina te uzimanje mikrobiolo&#x0161;kih uzoraka). Ovisno o te&#x017E;ini klini&#x010D;ke slike i djetetovu stanju, indicirano je i pro&#x0161;irenje dijagnosti&#x010D;ke obrade (PV, APTV, fibrinogen, D-dimeri, AST, ALT, GGT, ALP, CK, bilirubin, ureja, kreatinin, ionogram, acidobazni status, laktat, amonijak), a za isklju&#x010D;enje infekcije sredi&#x0161;njega &#x017E;iv&#x010D;anog sustava nu&#x017E;na je i lumbalna punkcija. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>&#x2013;<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Nakon uzimanja mikrobiolo&#x0161;kih uzoraka (hemokultura, urinokultura, obrisak pupka ili promjene na ko&#x017E;i, uzorak likvora te, prema potrebi, stolica) indicirano je &#x0161;to prije zapo&#x010D;eti dvojnu empirijsku antimikrobnu terapiju ampicilinom (100 &#x2013; 150 mg/kg/dan podijeljeno u tri doze) i gentamicinom (4 mg/kg/dan u jednoj dozi). (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Nema li drugih komplikacija, za izlje&#x010D;enje je dovoljno 10 &#x2013; 14 dana terapije. Pri razvoju meningitisa doza ampicilina povisuje se do 300 mg/kg/dan podijeljeno u 3 &#x2013; 4 doze (izme&#x0111;u ostalih uzro&#x010D;nika za pokrivanje BHS-B-a), a terapija, ovisno o te&#x017E;ini klini&#x010D;ke slike, traje 14 &#x2013; 21 dan. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>&#x2013;<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r21"><italic>21</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) Pri visokoj suspektnoj gram-negativnoj septikemiji uz terapiju ampicilinom dodaje se cefalosporin tre&#x0107;e generacije (cefotaksim ili ceftriakson), s gentamicinom ili bez njega. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>&#x2013;<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r10"><italic>10</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
<p>Prema nekim autorima, (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) primjena terapije karbapenemima (meropenem, imipenem) djeluje povoljno na te&#x0161;ke infekcije uzrokovane gram-pozitivnim i gram-negativnim bakterijama, uklju&#x010D;uju&#x0107;i sojeve ESBL-a, koji su sve u&#x010D;estaliji u op&#x0107;oj populaciji. Vankomicin se, pak, uvodi u terapiju ako u op&#x0107;oj populaciji postoji visoka prevalencija soja MRSA. Nakon prispije&#x0107;a negativnih mikrobiolo&#x0161;kih nalaza terapija vankomicinom trebala bi se ukinuti. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
<p>Antimikrobna terapija mijenja se ovisno o etiolo&#x0161;kom uzro&#x010D;niku, pristiglom nalazu antibiograma, epidemiolo&#x0161;koj situaciji na odre&#x0111;enom odjelu ili u bolnici te stajali&#x0161;tu ustanove u kojoj se dijete lije&#x010D;i, i prekida pri kontinuirano dobrom op&#x0107;em stanju djeteta, bez klini&#x010D;kih i hematolo&#x0161;ko-biokemijskih znakova upale te uz vi&#x0161;ekratno negativne nalaze kontrolnih mikrobiolo&#x0161;kih uzoraka. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>&#x2013;<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
<p>Za dijagnozu sepse u novoro&#x0111;en&#x010D;eta karakteristi&#x010D;ne su leukocitoza &gt; 20 (30) &#x00D7; 10<sup>9</sup>/L ili leukopenija &lt; 4 &#x2013; 5 &#x00D7; 10<sup>9</sup>/L, povi&#x0161;ena vrijednost nesegmentiranih granulocita vi&#x0161;a od 10 (20)%, a visoku osjetljivost (90%) i visoku negativnu prediktivnu vrijednost (98%) ima omjer nesegmentiranih neutrofila/ukupan broj neutrofila &gt; 0,2. Nadalje, na sepsu upu&#x0107;uje vrijednost trombocita ni&#x017E;a od 100 &#x00D7; 10<sup>9</sup>/L, a mogu&#x0107; je i poreme&#x0107;en sustav koagulacije. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Povi&#x0161;ene vrijednosti C-reaktivnog proteina (&gt; 10 &#x2013; 12 mg/L) imaju prosje&#x010D;nu senzitivnost od 45%, 95%-tnu specifi&#x010D;nost, 30%-tnu pozitivnu prediktivnu vrijednost i negativnu prediktivnu vrijednost od 30%. Vi&#x0161;e je autora suglasno da vrijednost prokalcitonina (PCT-a) vi&#x0161;a od 2 ng/mL ima osjetljivost i specifi&#x010D;nost od 80 do 100%, PPV do 80% i NPV do 100%. Op&#x0107;enito govore&#x0107;i, vrijednost PCT-a od 0,5 do 2 ng/mL nosi (relativno) nizak rizik od sepse, 2 &#x2013; 10 ng/mL srednji rizik, dok vrijednost vi&#x0161;a od 10 ng/mL donosi visok rizik od neonatalne sepse. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>&#x2013;<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) Veliki nesklad izme&#x0111;u (arbitrarne) gornje granice patolo&#x0161;kih nalaza zasigurno utje&#x010D;e na odluku o zapo&#x010D;injanju lije&#x010D;enja, broju hospitalizacija, duljini bolni&#x010D;kog lije&#x010D;enja i samoj epidemiologiji novoro&#x0111;ena&#x010D;ke sepse. Me&#x0111;utim, indikativno je da klini&#x010D;ka slika, pozitivan odgovor na primijenjenu antimikrobnu terapiju i pozitivan nalaz uzetih mikrobiolo&#x0161;kih uzoraka zajedni&#x010D;ki mogu s velikom vjerojatno&#x0161;&#x0107;u upozoriti na novoro&#x0111;ena&#x010D;ku sepsu.</p>
<p>Pri razvoju septi&#x010D;kog &#x0161;oka uz boluse teku&#x0107;ine lijek izbora za inotropnu potporu jest noradrenalin, alfa i beta-agonist koji, ovisno o primijenjenoj dozi (0,05 do 2 &#x03BC;g/kg/min), svojim vazokonstriktornim djelovanjem pove&#x0107;ava sistemsku vaskularnu rezistenciju. Naime, istra&#x017E;ivanja su pokazala da se noradrenalinom posti&#x017E;u vi&#x0161;i srednji arterijski tlak (engl. <italic>Mean arterial pressure</italic> &#x2013; MAP), vi&#x0161;i sredi&#x0161;nji venski tlak (engl. <italic>Central venous pressure</italic> &#x2013; CVP), bolja diureza uz ni&#x017E;i rizik od intrakranijalnog krvarenja. Ni&#x017E;e vrijednosti laktata kao posljedica navedenog djelovanja usko su povezane s ni&#x017E;om stopom mortaliteta i kra&#x0107;om hospitalizacijom. Primjena dopamina u djece se ne preporu&#x010D;uje zbog proaritmogenog djelovanja, povi&#x0161;enog rizika od intrakranijalnog krvarenja i ve&#x0107;eg mortaliteta. Ipak, u navedenim radovima zaklju&#x010D;eno je da su potrebna dodatna istra&#x017E;ivanja i na pedijatrijskoj populaciji s naglaskom na neonatalnu dob. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>&#x2013;<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>)</p>
<p>Nekoliko je istra&#x017E;ivanja u kojima je vidljivo da u stanju sepse novoro&#x0111;en&#x010D;ad, kao i djeca i odrasli, mo&#x017E;e oboljeti od relativne i apsolutne adrenalne insuficijencije zbog poja&#x010D;ane rezistencije na kortizol i op&#x0107;enito smanjenih zaliha adrenalnih hormona. Stoga je kod &#x0161;oka rezistentnog na primjenu bolusa teku&#x0107;ine i katekolamina indicirana primjena hidrokortizona (30 &#x2013; 50 mg/m<sup>2</sup>) jer on svojim djelovanjem smanjuje razgradnju katekolamina, povisuje koncentraciju intracelularnog kalcija u stanicama miokarda i mijenja (engl. <italic>upregulation</italic>, tj. pove&#x0107;ava osjetljivost na) adrenergi&#x010D;ke receptore. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>&#x2013;<xref ref-type="bibr" rid="r33"><italic>33</italic></xref>, <xref ref-type="bibr" rid="r43"><italic>43</italic></xref>, <xref ref-type="bibr" rid="r44"><italic>44</italic></xref>) Vazopresin se tako&#x0111;er rabi u lije&#x010D;enju hipotenzije neosjetljive na primjenu katekolamina povisuju&#x0107;i krvni tlak i snizuju&#x0107;i plu&#x0107;nu hipertenziju. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>&#x2013;<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>, <xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Indikativno je da davanje inotropne terapije nala&#x017E;e kontinuirano mjerenje vitalnih funkcija, sredi&#x0161;njega venskog tlaka, diureze i ostalih parametara u jedinicama intenzivnog lije&#x010D;enja specijaliziranima za lije&#x010D;enje novoro&#x0111;en&#x010D;adi.</p>
</sec>
<sec sec-type="other2">
<title>Stanja koja mogu opona&#x0161;ati klini&#x010D;ku sliku kasne novoro&#x0111;ena&#x010D;ke sepse</title>
<p>Dalje u tekstu navedena su stanja koja mogu izgledati kao novoro&#x0111;ena&#x010D;ka sepsa.</p>
<sec>
<title>Bronhiolitis (te&#x0161;ka klini&#x010D;ka slika)</title>
<p>Bronhiolitis je jedna od naj&#x010D;e&#x0161;&#x0107;ih infekcija novoro&#x0111;ena&#x010D;ke i dojena&#x010D;ke dobi koja naj&#x010D;e&#x0161;&#x0107;e iziskuje bolni&#x010D;ko lije&#x010D;enje u prva tri mjeseca &#x017E;ivota. Etiolo&#x0161;ki uzro&#x010D;nici koji dominiraju ponajprije su respiratorni sincicijski virus (RSV), zatim virus parainfluence, metapneumovirusi (hMPV), bokavirusi (BoV) te adenovirusi i rinovirusi. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>, <xref ref-type="bibr" rid="r45"><italic>45</italic></xref>&#x2013;<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>) Javlja se u kasnu jesen i u zimskim mjesecima, a naj&#x010D;e&#x0161;&#x0107;e se prenosi s prehla&#x0111;enih uku&#x0107;ana dodirom i kaplji&#x010D;nim putem. Bolest po&#x010D;inje respiratornim katarom, naj&#x010D;e&#x0161;&#x0107;e bez febriliteta, da bi za nekoliko dana zahvatila donje di&#x0161;ne putove u kojima zbog upalnih procesa nastaje opstrukcija na razini malih di&#x0161;nih putova. Klini&#x010D;ki se o&#x010D;ituje sekrecijom iz nosa, tahidispnejom (&#x0161;irenjem nosnica, klimanjem glavice, stenjanjem), pjenu&#x0161;avim sekretom u usnoj &#x0161;upljini i oslabljenim apetitom s te&#x0161;ko&#x0107;ama hranjenja zbog zaka&#x0161;ljavanja tijekom obroka. Auskultatorno se nad plu&#x0107;ima &#x010D;uje difuzno produljen ekspirij sa sipnjom i krepitacijama. U te&#x017E;ih bolesnika mogu&#x0107;e su bradipneja ili &#x010D;ak apnoi&#x010D;ke krize, superinfekcija s upalom plu&#x0107;a, dehidracija zbog oslabljenoga peroralnog unosa, a zbog ote&#x017E;anog hranjenja mo&#x017E;e nastati i aspiracijska pneumonija. Rezultati nu&#x017E;ne hematolo&#x0161;ko-biokemijske obrade neupadljivi su, a radiografskom snimkom plu&#x0107;a registrira se hiperinflacija s mogu&#x0107;im atelektazama. U bakterijskoj superinfekciji karakteristi&#x010D;ni su povi&#x0161;eni upalni parametri, dok se radiografski mo&#x017E;e registrirati formirani upalni infiltrat, koji je kod aspiracijske pneumonije tipi&#x010D;no smje&#x0161;ten u apikalnim dijelovima desnoga plu&#x0107;nog krila. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r21"><italic>21</italic></xref>, <xref ref-type="bibr" rid="r45"><italic>45</italic></xref>&#x2013;<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>)</p>
<p>Bronhiolitis se, prema najnovijim smjernicama, lije&#x010D;i simptomatski &#x2013; obilnim ispiranjem nosa fiziolo&#x0161;kom otopinom te inhalacijama fiziolo&#x0161;kom i hipertoni&#x010D;kom otopinom (naj&#x010D;e&#x0161;&#x0107;e 3%-tni NaCl). Unato&#x010D; prija&#x0161;njim preporukama terapija racemi&#x010D;nim epinefrinom, sistemskim kortikosteroidima i &#x03B2;-agonistima (salbutamol) nema dokazan klini&#x010D;ki u&#x010D;inak. Ne preporu&#x010D;uje se ni fizikalna terapija. Terapija kisikom daje se sukladno vrijednostima SO<sub>2</sub> (kad su vrijednosti ni&#x017E;e od 90%), dok je kontinuirana uporaba pulsne oksimetrije nu&#x017E;na. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>, <xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) U te&#x017E;ih bolesnika preporu&#x010D;uje se primjena kisika preko nosne kanile velikog protoka (engl. <italic>High-Flow Nasal Cannula</italic> &#x2013; HFNC), rje&#x0111;e i invazivna mehani&#x010D;ka ventilacija. Bakterijska superinfekcija lije&#x010D;i se antimikrobnom terapijom za upalu plu&#x0107;a, kao i u djece bez bronhiolitisa. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>, <xref ref-type="bibr" rid="r23"><italic>23</italic></xref>, <xref ref-type="bibr" rid="r24"><italic>24</italic></xref>, <xref ref-type="bibr" rid="r26"><italic>26</italic></xref>, <xref ref-type="bibr" rid="r45"><italic>45</italic></xref>&#x2013;<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Novoro&#x0111;en&#x010D;e s te&#x0161;kom klini&#x010D;kom slikom i/ili aspiracijskom pneumonijom doima se septi&#x010D;no, no kvalitetno uzeta anamneza i klini&#x010D;ki status s radiolo&#x0161;kom potvrdom bolesti ili bez nje mo&#x017E;e nas navesti na kona&#x010D;nu dijagnozu, a do tada se prema djetetu postupa kao bolesniku s kasnom novoro&#x0111;ena&#x010D;kom sepsom.</p>
</sec>
<sec>
<title>Hripavac (pertusis, &#x201E;magare&#x0107;i ka&#x0161;alj&#x201C;)</title>
<p>Hripavac je respiratorna bolest uzrokovana bakterijama <italic>Bordetella pertussis</italic> ili <italic>Bordetella parapertussis</italic> koja se &#x2013; za razliku od bronhiolitisa &#x2013; javlja u ljetnim mjesecima. Recidiviraju&#x0107;e apneje, letargija, tahikardija i u terminalnim stadijima bradikardija s kardiopulmonalnim zatajenjem znakovi su hripavca koji mogu opona&#x0161;ati klini&#x010D;ku sliku kasne novoro&#x0111;ena&#x010D;ke sepse, stoga je i hripavac, iako rijedak, ipak jedna od tema ovog rada. U odraslih i ve&#x0107;e djece pertusis je ve&#x0107;inom blaga respiratorna bolest koja se nakon inkubacije od 7 do 21-og dana razvija tijekom tri stadija. Kataralni stadij traje tjedan dana i prezentacijom potpuno odgovara virusnim infekcijama gornjega di&#x0161;nog sustava. Paroksizmalni stadij traje 3 &#x2013; 4 tjedna i karakteriziran je napadajima intenzivnog ka&#x0161;lja tijekom ekspirija nakon &#x010D;ega slijedi gr&#x010D;evit udisaj poput hripanja ili ka&#x0161;lja nalik glasanju magarca (po &#x010D;emu je bolest i dobila ime). Napadaji su &#x010D;esto pra&#x0107;eni crvenilom lica, protruzijom jezika, katkad cijanozom. Mogu se javiti i neurolo&#x0161;ke komplikacije (konvulzije, gluho&#x0107;a, sljepo&#x0107;a). Tre&#x0107;i je stadij rekonvalescentni stadij, koji mo&#x017E;e trajati i nekoliko mjeseci. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>&#x2013;<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Novoro&#x0111;en&#x010D;ad i mlada dojen&#x010D;ad mogu se prezentirati atipi&#x010D;nom klini&#x010D;kom slikom: u toj populaciji kataralni stadij &#x010D;esto izostaje ili je izrazito kratak, a karakteristi&#x010D;ni napadaji hripanja gotovo redovito izostaju. Mogu&#x0107;e komplikacije hripavca jesu te&#x0161;ka pneumonija, respiratorna insuficijencija, pertusi&#x010D;na encefalopatija i kardijalna dekompenzacija. (<xref ref-type="bibr" rid="r52"><italic>52</italic></xref>, <xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Zbog te&#x017E;ine stanja i mogu&#x0107;ih komplikacija djeca s hripavcem nerijetko trebaju skrb u jedinicama intenzivnog lije&#x010D;enja. Laboratorijski se registrira znatna leukocitoza (vi&#x0161;e od 20 &#x00D7; 10<sup>9</sup>/L, katkad i vi&#x0161;a od 50 &#x00D7; 10<sup>9</sup>/L) uz apsolutnu limfocitozu, &#x010D;ime se hripavac razlikuje od infekcije uzrokovane drugim bakterijskim uzro&#x010D;nicima. Vi&#x0161;e vrijednosti leukocita direktno su proporcionalne sa smrtno&#x0161;&#x0107;u. Radiografski nalaz &#x010D;esto je nespecifi&#x010D;an, ali mogu se vidjeti infiltrati u donjem ili srednjem re&#x017E;nju desnoga plu&#x0107;nog krila. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>&#x2013;<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>) Uzro&#x010D;nik se dokazuje ponajprije PCR-om, dok je kultivacija na hranili&#x0161;tu gotovo napu&#x0161;tena. Bolest se lije&#x010D;i primjenom azitromicina u dozi od 10 do 12 mg/kg tijekom tri do pet dana uz ostalu suportivnu terapiju. Primjena kortikosteroida i salbutamola nije se pokazala u&#x010D;inkovitom. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>&#x2013;<xref ref-type="bibr" rid="r53"><italic>53</italic></xref>) Iako je aktivna imunizacija acelularnim cjepivom znatno reducirala broj oboljelih, hripavac i dalje ostaje mogu&#x0107;i uzrok pobola i smrtnosti novoro&#x0111;en&#x010D;adi i mlade dojen&#x010D;adi koji se mogu prezentirati klini&#x010D;kom slikom kasne novoro&#x0111;ena&#x010D;ke sepse. Stoga se preporu&#x010D;uje docjepljivanje svih uku&#x0107;ana (strategija <italic>cocooning</italic>), pa i trudnica u tre&#x0107;em tromjese&#x010D;ju (maternalna strategija) ili barem postpartalno kako bi se aktivnom imunizacijom smanjila incidencija bolesti u najugro&#x017E;enijih skupina bolesnika. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>, <xref ref-type="bibr" rid="r51"><italic>51</italic></xref>, <xref ref-type="bibr" rid="r54"><italic>54</italic></xref>)</p>
</sec>
<sec>
<title>Supraventrikularna tahikardija</title>
<p>Supraventrikularna tahikardija (SVT) naj&#x010D;e&#x0161;&#x0107;a je aritmija u pedijatrijskoj i neonatolo&#x0161;koj populaciji, s incidencijom 1: 250 novoro&#x0111;en&#x010D;adi. Nu&#x017E;no je primarno isklju&#x010D;iti sinusnu tahikardiju koja se javlja u sklopu infekcije s febrilitetom uz bol, djetetovu uznemirenost, anemiju, hipovolemiju, zatajenje srca te nakon primjene nekih lijekova. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>&#x2013;<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r58"><italic>58</italic></xref>&#x2013;<xref ref-type="bibr" rid="r63"><italic>63</italic></xref>) Stanje sepse tako&#x0111;er uzrokuje sinusnu tahikardiju, dok odre&#x0111;ene supraventrikularne tahikardije mogu stvarati diferencijalnodijagnosti&#x010D;ku dilemu zbog sli&#x010D;ne prezentacije. Za sinusnu tahikardiju karakteristi&#x010D;no je da nastane postupno i prestane polagano nakon lije&#x010D;enja osnovnog uzroka. Njezina je frekvencija ispod 220/min, u EKG-u su P-valovi prisutni, pozitivno usmjereni u I. i aVF-odvodu, prethode QRS-kompleksu, PR-intervali su jednaki, a postoji i odre&#x0111;ena R-R-varijabilnost. SVT je karakteriziran frekvencijom iznad 220/min, P-valovi su odsutni ili neprepoznatljivi, mogu biti invertirani u II., III. i aVF-odvodu, s nevarijabilno&#x0161;&#x0107;u R-R-intervala te (u odsutnosti bloka grane ili preekscitacije) uskim QRS-kompleksima. SVT redovito brzo nastane i prekine se iznenadno (spontano ili nakon intervencije). Mo&#x017E;e se podijeliti u atrijsku tahikardiju (ektopi&#x010D;nu atrijsku tahikardiju, multifokalni AT, fibrilaciju ili undulaciju atrija), atrioventrikularnu nodalnu kru&#x017E;nu tahikardiju (engl. <italic>Atrioventricular nodal reentrant tachycardia</italic> &#x2013; AVNRT) te atrioventrikularnu kru&#x017E;nu tahikardiju (engl. <italic>Atrioventricular reentrant tachycardia</italic> &#x2013; AVRT). Atrioventrikularna nodalna kru&#x017E;na tahikardija (AVNRT) nastaje kru&#x017E;enjem u podru&#x010D;ju AV-&#x010D;vora (<italic>nodusa</italic>) i rijetka je u novoro&#x0111;ena&#x010D;koj dobi. Pri pojavi AVRT-a s ortodromnim provo&#x0111;enjem val depolarizacije &#x0161;iri se u ventrikul redovitim provodnim putem i vra&#x0107;a akcesornim provodnim putem retrogradno, dok u antedromnom provo&#x0111;enju val iz atrija u ventrikul putuje akcesornim putem (anterogradnim tokom) i vra&#x0107;a se preko normalnoga provodnog puta. Ortodromni AVRT naj&#x010D;e&#x0161;&#x0107;i je SVT, javlja se u oko 90% djece i naj&#x010D;e&#x0161;&#x0107;e se manifestira u sklopu Wolff-Parkinson-Whiteova (WPW) sindroma. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>&#x2013;<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r58"><italic>58</italic></xref>&#x2013;<xref ref-type="bibr" rid="r63"><italic>63</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>) Daljnje podjele i elektrofiziolo&#x0161;ki mehanizmi nastanka prelaze okvire ovog pregleda.</p>
<p>Klini&#x010D;ki se SVT koji traje odre&#x0111;eno vrijeme manifestira gotovo jednako kao sepsa &#x2013; novoro&#x0111;en&#x010D;e je letargi&#x010D;no, slabo jede, oznojeno, blijede boje ko&#x017E;e, oslabljenih perifernih pulzacija s produljenim kapilarnim punjenjem. Ako aritmija perzistira, sr&#x010D;ana dekompenzacija mo&#x017E;e nastati u roku od 24 do 48 sati pa je brzo prepoznavanje i lije&#x010D;enje veoma va&#x017E;no. Kod hemodinamske nestabilnosti ili nemogu&#x0107;nosti postavljanja venskog puta radi se sinkronizirana kardioverzija inicijalnom energijom od 1 J/kg pa se, do&#x0111;e li do neuspjeha, navedena energija udvostru&#x010D;uje na 2 J/kg. (<xref ref-type="bibr" rid="r55"><italic>55</italic></xref>&#x2013;<xref ref-type="bibr" rid="r64"><italic>64</italic></xref>) Ako je dijete cirkulatorno stabilno, prekid aritmije treba zapo&#x010D;eti stavljanjem leda ili hladnog obloga na lice novoro&#x0111;en&#x010D;eta.</p>
<p>Osim navedenoga, vagalni manevri koji dolaze u obzir jesu i povi&#x0161;enje intraabdominalnog i intratorakalnog tlaka (savijanjem nogu u kukovima uz lagano pritiskanje trbuha, tj. polo&#x017E;aj &#x201E;&#x017E;abe&#x201C;). Kompresija o&#x010D;nih bulbusa zbog mogu&#x0107;nosti ozljede nije dopu&#x0161;tena, kao ni masa&#x017E;a karotidnog sinusa jer kompromitira di&#x0161;ni put i pogor&#x0161;ava cerebralni protok. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>&#x2013;<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r60"><italic>60</italic></xref>&#x2013;<xref ref-type="bibr" rid="r64"><italic>64</italic></xref>) Ne postigne li se uspjeh, uz nu&#x017E;no kontinuirano snimanje EKG-a, primjenjuje se brzi bolus adenozina u dozi od 0,1 mg/kg (maks. 6 mg). Idu&#x0107;a bi doza trebala biti dvaput vi&#x0161;a &#x2013; 0,2 mg/kg (maks. 12 mg). Pri ponovnom neuspjehu, u dogovoru s kardiologom daju se propafenon u dozi od 1 do 2 mg/kg inicijalno, amiodaron 5 mg/kg (maks. 15 mg/kg/dan) ili bilo koji dostupan intravenski &#x03B2;-blokator. Beta-blokatori i amiodaron ne smiju se kombinirati zbog nastanka hipotenzije. (<xref ref-type="bibr" rid="r59"><italic>59</italic></xref>&#x2013;<xref ref-type="bibr" rid="r63"><italic>63</italic></xref>) Ca blokatori (npr., verapamil) ne daju se dojen&#x010D;adi zbog visokog rizika od ekstremne bradikardije i refraktorne hipotenzije, a kontraindicirani su u primjeni kod WPW sindroma. Prije &#x0161;iroko primjenjivan digoksin kontraindiciran je zbog proaritmogenog djelovanja. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>&#x2013;<xref ref-type="bibr" rid="r64"><italic>64</italic></xref>) Elektrofiziolo&#x0161;ka ispitivanja s ablacijom proaritmogenog supstrata prija&#x0161;njih su godina bila odga&#x0111;ana za djecu koja su starija od 18 mjeseci i/ili tjelesnom masom iznad 15 kg. Unato&#x010D; ograni&#x010D;enim radovima novije spoznaje upu&#x0107;uju na to da je takvo invazivno lije&#x010D;enje (radiofrekventna ablacija i krioablacija) mogu&#x0107;e i za manju djecu bez znatnih komplikacija (osobito u obliku razvoja perzistentnog AV-bloka), s naglaskom da su desnostrani akcesorni provodni putovi ipak udru&#x017E;eni s ne&#x0161;to ve&#x0107;im neuspjehom same dijagnosti&#x010D;ko-terapijske intervencije od ljevostranih. (<xref ref-type="bibr" rid="r62"><italic>62</italic></xref>&#x2013;<xref ref-type="bibr" rid="r67"><italic>67</italic></xref>) &#x010C;ini se da su jedini ograni&#x010D;avaju&#x0107;i &#x010D;imbenici iskustvo i stajali&#x0161;te interventnoga dje&#x010D;jeg kardiologa. Zahvati kod male djece, tek nakon pomnog odmjeravanja rizika i koristi, provode se u malobrojnim europskim centrima izvrsnosti s posebnim iskustvom u pedijatrijskoj elektrofiziologiji. Odnedavno se takva djeca mogu lije&#x010D;iti i u na&#x0161;oj dr&#x017E;avi u sklopu Referentnog centra za aritmije i elektrofiziologiju srca.</p>
</sec>
<sec>
<title>Sr&#x010D;ane gre&#x0161;ke ovisne o arterijskom (Botallovu) duktusu</title>
<p>Prevalencija priro&#x0111;enih sr&#x010D;anih gre&#x0161;aka jest 7 &#x2013; 8&#x2030;; od toga ih 60% otpada na VSD (ventrikularni septalni defekt), ASD (atrijski septalni defekt) i PDA (perzistentni arterijski duktus). (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>&#x2013;<xref ref-type="bibr" rid="r71"><italic>71</italic></xref>) Dio sr&#x010D;anih gre&#x0161;aka ovisnih o otvorenosti arterijskog kanala, osim cijanozom, primarno se prezentira klini&#x010D;kom slikom sepse, a neprepoznate i/ili neadekvatno lije&#x010D;ene imaju visoku stopu smrtnosti pa su zato predmet ovog rada. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>&#x2013;<xref ref-type="bibr" rid="r71"><italic>71</italic></xref>)</p>
<p>Osim Clarkove klasifikacije prema patogenezi, (<xref ref-type="bibr" rid="r72"><italic>72</italic></xref>) sr&#x010D;ane gre&#x0161;ke mogu se podijeliti i prema patofiziologiji. (<xref ref-type="bibr" rid="r71"><italic>71</italic></xref>) Op&#x0107;enito se dijele na ljevostrane opstruktivne lezije, koje imaju poja&#x010D;an protok krvi kroz plu&#x0107;nu cirkulaciju, a nedostatan u sistemskoj cirkulaciji, zatim desnostrane opstruktivne lezije, tj. one sa smanjenim protokom kroz plu&#x0107;a, sr&#x010D;ane gre&#x0161;ke s paralelnom cirkulacijom te gre&#x0161;ke s potpunim mije&#x0161;anjem krvi (<xref ref-type="table" rid="t2">Table 2</xref>). Neke sr&#x010D;ane gre&#x0161;ke o&#x010D;ituju se (u ve&#x0107;ini slu&#x010D;ajeva) ve&#x0107; u prvim satima ili danima &#x017E;ivota s klini&#x010D;kim znakovima &#x0161;oka zbog kompromitacije krvotoka. U njih se ubrajaju sindromi hipoplasti&#x010D;noga lijevog i desnog srca te trikuspidalna i pulmonalna atrezija bez VSD-a. Druge (transpozicija velikih krvnih &#x017E;ila bez VSD-a, trunkus arteriozus, aortopulmonalni prozor, ekstremni oblik Fallotove tetralogije (TOF), totalni anomalni utok plu&#x0107;nih vena (TAUPV)) prezentiraju se ve&#x0107; u prvom tjednu respiratornim distresom uz izra&#x017E;enu cijanozu pa se vrlo brzo postavlja sumnja na priro&#x0111;enu sr&#x010D;anu gre&#x0161;ku.</p>
<table-wrap id="t2" position="float">
<label>Table 2</label><caption><title>Pathophysiologic classification of congenital heart disease (modified after reference <xref ref-type="bibr" rid="r71">71</xref>)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="100%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x00A0;&#x00A0;Ljevostrane opstruktivne lezije/Left-sided obstructive lesions &#x2013; kriti&#x010D;na koarktacija aorte/critical coarctation of aorta (CoA)<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; prekid luka aorte/interruption of aortic arch<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; kriti&#x010D;na aortalna stenoza bez ventrikularnoga septalnog defekta (VSD)/critical aortic stenosis with intact ventricular septum<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; sindrom hipoplasti&#x010D;noga lijevog srca/hypoplastic left heart syndrome (HLHS)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x00A0;&#x00A0;Desnostrane opstruktivne lezije/Right-sided obstructive lesions<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; pulmonalna atrezija bez VSD-a/pulmonary atresia with intact ventricular septum<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; kriti&#x010D;na pulmonalna stenoza bez VSD-a/critical pulmonary stenosis with intact ventricular septum<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; ekstreman oblik Fallotove tetralogije (TOF)/extreme form of tetralogy of Fallot<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; trikuspidalna atrezija/tricuspid atresia<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; te&#x0161;ka Ebsteinova anomalija/severe Ebstein&#x2019;s anomaly<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; sindrom hipoplasti&#x010D;noga desnog srca/hypoplastic right heart syndrome (HRHS)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">&#x00A0;&#x00A0;Sr&#x010D;ane gre&#x0161;ke s potpunim mije&#x0161;anjem krvi/CHD with complete mixing of blood &#x2013; truncus arteriosus (TA)<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; aortopulmonalni prozor/aortopulmonary window<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; totalni anomalni utok plu&#x0107;nih vena u desni atrij (TAUPV)/total anomalous pulmonary venous return (TAPVR)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">&#x00A0;&#x00A0;Sr&#x010D;ane gre&#x0161;ke s paralelnom cirkulacijom/CHD with parallel circulation<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2013; transpozicija velikih krvnih &#x017E;ila/transposition of great arteries<break/>&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;(d-TGA)</td>
</tr>
</tbody></table></table-wrap>
<p>Za ovaj su prikaz va&#x017E;ni: prekid luka aorte, kriti&#x010D;na aortalna stenoza i koarktacija aorte. Njih karakterizira prisutnost sr&#x010D;anog &#x0161;uma pa se nerijetko dijagnoza postavlja u samom rodili&#x0161;tu nakon ehokardiografske procjene konzultiranoga pedijatrijskog kardiologa. Ako se djeca neprepoznata otpuste ku&#x0107;i, medijan klini&#x010D;ke manifestacije trenutak je zatvaranja Botallova duktusa na prijelazu iz prvog u drugi tjedan &#x017E;ivota. Novoro&#x0111;en&#x010D;ad se prezentira tahikardijom, tahipnejom bez dispneje, prvotno blijedo-sivkastim koloritom, poslije cijanozom uz sni&#x017E;ene vrijednosti SO<sub>2</sub>. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>) Test hiperoksije mo&#x017E;e pomo&#x0107;i pri razlu&#x010D;ivanju sr&#x010D;anog od plu&#x0107;nog uzroka cijanoze. On se izvodi davanjem 100%-tnog kisika preko maske sa spremnikom, na &#x0161;to se u cijanozi kardijalne geneze ne bilje&#x017E;i pobolj&#x0161;anje ili normalizacija SO<sub>2</sub>, tj. izostaje porast pO<sub>2</sub> koji ne prelazi 1,5 &#x2013; 4 kPa. Nu&#x017E;ni su i radiografska obrada toraksa radi isklju&#x010D;enja intrapulmonalnih zbivanja te ultrazvuk srca koji je ujedno i zlatni standard za postavljanje dijagnoze sr&#x010D;ane gre&#x0161;ke. Pri osnovanoj sumnji u sve cijanoti&#x010D;ne novoro&#x0111;en&#x010D;adi do ehokardiografske potvrde dijagnoze daje se Prostin VR (aloprostadil, prostaglandin E<sub>1</sub> &#x2013; PGE) u dozi od 0,05 do 0,1 &#x03BC;g/kg/min iv. (maksimalna doza 0,4 &#x03BC;g/kg/min). Doza se mo&#x017E;e postupno sni&#x017E;avati, ali uz ehokardiografski nadzor prohodnosti Botallova duktusa. Osim febriliteta, hipotenzije i proljeva, glavna nuspojava Prostina VR jest apneja pa se, ako je indicirano, mo&#x017E;e dati aminofilin u dozi od 5 mg/kg iv. inicijalno tijekom 20 min, a zatim kontinuirano 0,2 mg/kg/h. (<xref ref-type="bibr" rid="r60"><italic>60</italic></xref>, <xref ref-type="bibr" rid="r61"><italic>61</italic></xref>, <xref ref-type="bibr" rid="r68"><italic>68</italic></xref>, <xref ref-type="bibr" rid="r70"><italic>70</italic></xref>, <xref ref-type="bibr" rid="r73"><italic>73</italic></xref>&#x2013;<xref ref-type="bibr" rid="r76"><italic>76</italic></xref>) Za kona&#x010D;nu dijagnozu u odgovaraju&#x0107;em centru izvrsnosti kod nekih priro&#x0111;enih sr&#x010D;anih gre&#x0161;aka radi se kateterizacija srca kako bi se upotpunio dijagnosti&#x010D;ki slijed i stvorila kompletna slika o sr&#x010D;anoj gre&#x0161;ci. Ako je indicirano, kateterizacija srca u istom aktu mo&#x017E;e postati i terapijska jer se nakon vizualizacije sr&#x010D;anih struktura mo&#x017E;e napraviti balonska atrioseptostomija kojom se rastere&#x0107;uje desni atrij, omogu&#x0107;ava mije&#x0161;anje venske i arterijske krvi i pove&#x0107;ava priljev krvi u sistemski krvni optok. (<xref ref-type="bibr" rid="r77"><italic>77</italic></xref>) Navedeni postupci odga&#x0111;aju kona&#x010D;nu kardiokirur&#x0161;ku intervenciju do potpune kardiopulmonalne stabilizacije i mirne pripreme za kirur&#x0161;ki zahvat. Pri razvoju kardijalnog zatajenja s kardijalnim &#x0161;okom, prema novim spoznajama, dobutamin je lijek izbora. Dobutamin putem alfa, beta i dopaminergi&#x010D;kih receptora djeluje na smanjenje sistemske vaskularne rezistencije istodobno smanjuju&#x0107;i zaoptere&#x0107;enje uz pozitivno inotropno i kronotropno djelovanje te stimulaciju diureze preko vazodilatacije bubre&#x017E;nih arterija, bez znatnog u&#x010D;inka na krvni tlak. Primjenjuje se u dozi od 2 do 10 &#x03BC;g/kg/min, a kao i pri ostaloj inotropnoj terapiji, njegova je primjena rezervirana za jedinice intenzivnog lije&#x010D;enja uz kontinuirano pra&#x0107;enje vitalnih funkcija. Dopamin vi&#x0161;e nije lijek izbora jer osim proaritmogenog djelovanja pove&#x0107;ava sistemsku vaskularnu rezistenciju i time direktno optere&#x0107;uje ionako oslabljen miokard. U praksi je polako i sigurno svoje mjesto na&#x0161;ao i milrinon, inhibitor fosfodiesteraze koji odli&#x010D;no djeluje na kontraktilnost miokarda &#x2013; pobolj&#x0161;ava sistoli&#x010D;ku i dijastoli&#x010D;ku funkciju miokarda, smanjuje potrebu za kisikom i ne utje&#x010D;e znatnije na vazokonstrikciju i sistemski vaskularni otpor, smanjuju&#x0107;i time sr&#x010D;ano zaoptere&#x0107;enje. Usto, dobro djeluje na smanjenje plu&#x0107;ne vaskularne rezistencije uzrokuju&#x0107;i dilataciju plu&#x0107;nog krvo&#x017E;ilja putem du&#x0161;ikova oksida. Me&#x0111;utim, njegova primjena indicirana je samo u odsutnosti hipotenzije zbog mogu&#x0107;eg smanjenja koronarne perfuzije. Levosimendan povisuje unutarstani&#x010D;nu koncentraciju kalcija i time ima pozitivno inotropno djelovanje, ali bez aritmogenog u&#x010D;inka. (<xref ref-type="bibr" rid="r78"><italic>78</italic></xref>&#x2013;<xref ref-type="bibr" rid="r82"><italic>82</italic></xref>) Sve se &#x010D;e&#x0161;&#x0107;e indicira njegova primjena u jedinicama intenzivnog lije&#x010D;enja novoro&#x0111;en&#x010D;adi. U na&#x0161;oj zemlji ve&#x0107; se niz godina u nekoliko centara izvodi ehokardiografski probir na priro&#x0111;ene sr&#x010D;ane gre&#x0161;ke. Time se omogu&#x0107;avaju rana (prenatalna) dijagnoza sr&#x010D;ane gre&#x0161;ke i pravodobno davanje kontinuirane infuzije prostaglandina neposredno nakon ro&#x0111;enja te zbrinjavanje bolesnika u odgovaraju&#x0107;em centru izvrsnosti. Navedenim postupcima smanjuju se broj komplikacija te ukupni mortalitet i morbiditet novoro&#x0111;en&#x010D;adi sa sr&#x010D;anim anomalijama i, naposljetku, sni&#x017E;ava ukupan tro&#x0161;ak lije&#x010D;enja. (<xref ref-type="bibr" rid="r73"><italic>73</italic></xref>, <xref ref-type="bibr" rid="r83"><italic>83</italic></xref>, <xref ref-type="bibr" rid="r84"><italic>84</italic></xref>) Zbog ograni&#x010D;ene osjetljivosti te metode (60 &#x2013; 80%) (<xref ref-type="bibr" rid="r83"><italic>83</italic></xref>, <xref ref-type="bibr" rid="r84"><italic>84</italic></xref>) u brojnim je zemljama uveden i postnatalni probir na hemodinamski znatne sr&#x010D;ane gre&#x0161;ke pulsnom oksimetrijom kako bi se u ranoj fazi, prije zatvaranja Botallova duktusa, takva sr&#x010D;ana gre&#x0161;ka otkrila, dijete uputilo u odgovaraju&#x0107;u ustanovu i na vrijeme u&#x010D;inio spasonosni kirur&#x0161;ki zahvat sa &#x0161;to manje perioperativnih komplikacija. Iako su studije i dalje u tijeku, zasad je poznato da je specifi&#x010D;nost takvog testa, ovisno o centru i metodi probira, oko 95%, a osjetljivost ispod 75%. (<xref ref-type="bibr" rid="r100"><italic>100</italic></xref>&#x2013;<xref ref-type="bibr" rid="r104"><italic>104</italic></xref>) Stoga je potrebno daljnje pra&#x0107;enje probira kako bi se napravila visokokvalitetna metoda sa &#x0161;to manje la&#x017E;no negativnih i la&#x017E;no pozitivnih rezultata. (<xref ref-type="bibr" rid="r85"><italic>85</italic></xref>&#x2013;<xref ref-type="bibr" rid="r89"><italic>89</italic></xref>)</p>
</sec>
<sec>
<title>Hipoglikemija</title>
<p>Sni&#x017E;ena vrijednost glukoze u krvi u prvih 48 sati &#x017E;ivota javlja se u sklopu neprimjerenoga peroralnog unosa odnosno odgo&#x0111;enog hranjenja, tj. gladovanja novoro&#x0111;en&#x010D;adi. Razlozi tomu jesu &#x0161;to novoro&#x0111;en&#x010D;ad ima smanjene rezerve i oslabljenu mobilizaciju energije iz masnog tkiva s posljedi&#x010D;no smanjenom sposobno&#x0161;&#x0107;u prikladne korekcije ni&#x017E;ih vrijednosti glikemije. Ostali su uzroci tranzitorna hipoglikemija novoro&#x0111;en&#x010D;eta, hiperinzulinizam bilo koje etiologije i hipopituitarizam. Nakon 48 sati hipoglikemija mo&#x017E;e biti inicijalni znak niza metaboli&#x010D;kih bolesti (npr., neketoti&#x010D;ke hipoglikemije, poreme&#x0107;aja oksidacije masnih kiselina, defekata glukoneogeneze, poreme&#x0107;aja metabolizma ugljikohidrata...). Prema dana&#x0161;njim spoznajama i stajali&#x0161;tima, hipoglikemijom se smatra vrijednost glikemije ispod 2,6 mmol/L, dok se prije pretpostavljene vrijednosti (asimptomatskih hipoglikemija) u rasponu od 2,5 do 1,67 mmol/L zbog patolo&#x0161;kih somatosenzornih potencijala vi&#x0161;e ne uzimaju kao euglikemi&#x010D;ke. Klini&#x010D;ki se simptomatska hipoglikemija o&#x010D;ituje adrenergi&#x010D;kim simptomima: tahikardijom, tahipnejom, bljedilom, tremorom, intenzivnim pla&#x010D;em i iritabilno&#x0161;&#x0107;u, zatim kolinergi&#x010D;kim simptomima: oznojeno&#x0161;&#x0107;u te neuroglikopeni&#x010D;kim znakovima: letargijom, hipotonijom, poreme&#x0107;ajem svijesti, konvulzijama i komom. Nije rijedak ni nastanak generalizirane cijanoze zbog &#x010D;ega niska vrijednost glikemije potpuno opona&#x0161;a gore navedena klini&#x010D;ka stanja. Uz nu&#x017E;no uzimanje dodatnih biokemijskih nalaza (ketoni, inzulin, C-peptid, hormon rasta, ACTH, kortizol, amonijak), za pravovaljanu procjenu etiologije obvezatna je potvrda hipoglikemije i venskim uzorkovanjem krvi. Nakon verifikacije niskih vrijednosti &#x0161;e&#x0107;era u krvi odmah se primjenjuje bolus 10%-tne glukoze 2 &#x2013; 5 mL/kg, koji se mo&#x017E;e u nekoliko navrata ponoviti, a zatim se daje kontinuirana infuzija 5 &#x2013; 8 pa sve do 10 mg/kg/min. Uporaba glukagona rezervirana je za hiperinzulinizam i poreme&#x0107;aje svijesti bez mogu&#x0107;nosti uspostave venskog puta, a daje se u dozi od 0,025 do 0,3 mg/kg im. (<xref ref-type="bibr" rid="r90"><italic>90</italic></xref>&#x2013;<xref ref-type="bibr" rid="r93"><italic>93</italic></xref>, <xref ref-type="bibr" rid="r95"><italic>95</italic></xref>) U dijagnosti&#x010D;kom slijedu potrebno je isklju&#x010D;iti ostala klini&#x010D;ka stanja koja u podlozi imaju hipoglikemiju kao &#x0161;to su kongenitalna adrenalna hiperplazija, razne genske bolesti, sepsa, priro&#x0111;ene sr&#x010D;ane gre&#x0161;ke.</p>
</sec>
<sec>
<title>Kongenitalna adrenalna hiperplazija (s gubitkom soli)</title>
<p>Kongenitalna adrenalna hiperplazija (KAH) monogenska je bolest koja se naslje&#x0111;uje autosomno recesivno (gen CYP21A2 na kromosomu 6p21). (<xref ref-type="bibr" rid="r94"><italic>94</italic></xref>&#x2013;<xref ref-type="bibr" rid="r96"><italic>96</italic></xref>) Mu&#x0161;ka i &#x017E;enska djeca podjednako su zahva&#x0107;ena. U 90% slu&#x010D;ajeva uzrokovana je manjkom 21-hidroksilaze, enzima koji sudjeluje u sintezi kortizola s posljedi&#x010D;nim smanjenim stvaranjem tog hormona. S obzirom na to da je kortizol glavni regulator sekrecije ACTH, poja&#x010D;ano se izlu&#x010D;uju CRF (faktor izlu&#x010D;ivanja kortikotropina) i ACTH (adrenokortikotropni hormon), &#x0161;to rezultira ubrzanim stvaranjem intermedijarnih steroida uz hiperplaziju nadbubre&#x017E;ne &#x017E;lijezde. Postoje &#x010D;etiri oblika KAH-a uzrokovanog manjkom 21-hidroksilaze: potpuni defekt sa sindromom gubitka soli i nepotpuni ili parcijalni bez gubitka soli (klasi&#x010D;ni oblici) te neklasi&#x010D;ni simptomatski &#x2013; koji se javlja u kasnijoj dobi u obliku preuranjenog puberteta i neklasi&#x010D;ni asimptomatski oblik koji nema klini&#x010D;ke znakove poreme&#x0107;aja. Deficiti potonjih enzima manifestiraju se druga&#x010D;ijom klini&#x010D;kom slikom i nakon novoro&#x0111;ena&#x010D;ke dobi pa oni ne&#x0107;e biti predmetom ovog razmatranja. Budu&#x0107;i da se djevoj&#x010D;ice rode s dvosmislenim spolovilom zbog intrauterinog djelovanja viriliziraju&#x0107;ih hormona, dijagnoza se mo&#x017E;e postaviti ve&#x0107; u rodili&#x0161;tu, iako ima slu&#x010D;ajeva da se odre&#x0111;en broj djevoj&#x010D;ica proglasi dje&#x010D;acima sa slabije razvijenim spolovilom i neprepoznati se otpuste ku&#x0107;i. Dje&#x010D;aci nerijetko imaju samo tamnije pigmentiran skrotum, bez ostalih znakova i simptoma. Klini&#x010D;ka manifestacija bolesti javlja se naj&#x010D;e&#x0161;&#x0107;e u drugom tjednu &#x017E;ivota u obliku adrenalne krize s dehidracijom, hipotenzijom, bljedilom, cijanozom, hladnom ko&#x017E;om oro&#x0161;enom znojem, s acidozom, hipoglikemijom i poreme&#x0107;ajem elektrolita &#x2013; hiponatremijom i hiperkalemijom. Zbog kasno postavljene dijagnoze djeca nerijetko umru od &#x0161;oka i kardiocirkulatornog zatajenja. Za dijagnozu je zapravo najva&#x017E;nije inicijalno postavljanje sumnje kako bi se brzom biokemijskom analizom (registriranim poreme&#x0107;ajem acidobaznog statusa i elektrolita) sumnja potvrdila i pravodobno zapo&#x010D;elo lije&#x010D;enje. Ono se sastoji u nadoknadi volumena, korekciji elektrolita i acidobaznog statusa te nadoknadi glukokortikoida. (<xref ref-type="bibr" rid="r90"><italic>90</italic></xref>, <xref ref-type="bibr" rid="r94"><italic>94</italic></xref>&#x2013;<xref ref-type="bibr" rid="r99"><italic>99</italic></xref>) Definitivna dijagnoza postavlja se hormonalnom obradom, tj. verificiranjem povi&#x0161;enih vrijednosti 17-hidroksiprogesterona (17-OHP), pregnantriola, ACTH i renina u plazmi uz uredne ili sni&#x017E;ene vrijednosti kortizola te povi&#x0161;ene razine adrenalnih androgena i 17-ketosteroida u urinu. (<xref ref-type="bibr" rid="r99"><italic>99</italic></xref>&#x2013;<xref ref-type="bibr" rid="r103"><italic>103</italic></xref>) Supstitucijskim lije&#x010D;enjem glukokortikoidima (hidrokortizon u dozi od 10 do 20 mg/m<sup>2</sup> u 3 doze, a u akutnoj krizi u triput vi&#x0161;oj dozi, tj. 30 &#x2013; 50 mg/m<sup>2</sup>) te mineralokortikoidima (fludrokortizon &#x2013; Florinef u dozi od 0,05 do 0,3 mg/dan) uz korekciju hipoglikemije i dehidracije te peroralnu nadoknadu NaCl 1 &#x2013; 3 g/dan (podijeljeno u tri doze) dolazi do normalizacije adrenalnih hormona, acidobazne i elektrolitske ravnote&#x017E;e. (<xref ref-type="bibr" rid="r94"><italic>94</italic></xref>&#x2013;<xref ref-type="bibr" rid="r99"><italic>99</italic></xref>) Time se posti&#x017E;u uredan rast i razvoj te prevenira nastanak preuranjenog puberteta sa svim somatskim i psihi&#x010D;kim posljedicama.</p>
</sec>
<sec>
<title>Metaboli&#x010D;ke bolesti</title>
<p>Bolesti metabolizma oduvijek su lije&#x010D;nicima bile diferencijalnodijagnosti&#x010D;ki i terapijski problem jer se s njima rijetko susre&#x0107;emo, o njima malo znamo, a medicinske su spoznaje o tim bolestima svakodnevno sve ve&#x0107;e i &#x0161;ire pa, zapravo, razvojem dodatnih dijagnosti&#x010D;kih metoda postaju najbr&#x017E;e rastu&#x0107;om znano&#x0161;&#x0107;u u sklopu pedijatrije.</p>
<p>U ovom pregledu primarno su izdvojene bolesti koje se doimaju kao kasna novoro&#x0111;ena&#x010D;ka sepsa i javljaju se u tom razdoblju. Metaboli&#x010D;ke bolesti manifestiraju se ovisno o osnovnome metaboli&#x010D;kom poreme&#x0107;aju. Neurolo&#x0161;kim simptomima (oslabljenim sisanjem i hranjenjem, hipotonijom, letargijom, poreme&#x0107;ajima svijesti) uz hiperamoniemiju s acidozom ili bez nje manifestiraju se galaktozemija, nasljedna intolerancija fruktoze, poreme&#x0107;aji ciklusa ureje, leucinoza te organske acidurije zbog poreme&#x0107;aja metabolizma aminokiselina razgranatog lanca (naj&#x010D;e&#x0161;&#x0107;e propionska i metilmalonska acidurija). Sli&#x010D;ni simptomi vidljivi su tijekom gladovanja djeteta s poreme&#x0107;ajem razgradnje masnih kiselina dugih lanaca, &#x0161;to se laboratorijski o&#x010D;ituje razvojem neketoti&#x010D;ke ili hipoketoti&#x010D;ke hipoglikemije. Djeca s poreme&#x0107;ajem glukoneogeneze, odre&#x0111;enim tipovima glikogenoze, poreme&#x0107;ajima beta-oksidacije masnih kiselina, nekim oblicima hiperinzulinizma, poreme&#x0107;ajem karnitinskog ciklusa i poreme&#x0107;ajem ketogeneze klini&#x010D;ki se o&#x010D;ituju mi&#x0161;i&#x0107;nom slabo&#x0161;&#x0107;u s ote&#x017E;anim uzimanjem obroka, mioglobinurijom, poreme&#x0107;ajima sr&#x010D;anog ritma i koagulopatijom. U njih se mo&#x017E;e registirati hipoglikemija s laktacidozom ili bez nje, s ketonemijom ili bez nje. Pri poreme&#x0107;aju mitohondrijskog stvaranja energije zbog manjka piruvat dehidrogenaze, poreme&#x0107;aja enzimskih kompleksa respiratornog lanca (koenzim Q, citokrom C...) te nedostatka enzima Krebsova ciklusa osnovni je problem laktacidemija koja uzrokuje hipotoniju, poreme&#x0107;aje svijesti s razvojem sr&#x010D;ane i respiratorne insuficijencije ili bez njega. Op&#x0107;enito govore&#x0107;i, u bolesnika s hiperamoniemijom, laktacidemijom i metaboli&#x010D;kom acidozom s jetrenom lezijom ili bez nje, mogu&#x0107;a je kompenzatorna respiratorna alkaloza. U takvim stanjima potreban je poseban oprez da se ne previdi te&#x017E;ina stanja. (<xref ref-type="bibr" rid="r90"><italic>90</italic></xref>, <xref ref-type="bibr" rid="r104"><italic>104</italic></xref>&#x2013;<xref ref-type="bibr" rid="r111"><italic>111</italic></xref>) Terapija je inicijalno simptomatska &#x2013; ovisno o tipu metaboli&#x010D;ke bolesti prekida se peroralni unos i daje se infuzija glukoze u visokoj koncentraciji (7 &#x2013; 10 mg/kg/min) kako bi se na vrijeme suzbio katabolizam. Uz navedeno mjerama detoksikacije prekida se dodatni priljev toksi&#x010D;nih spojeva. Prema potrebi, indicirane su i mehani&#x010D;ka ventilacija te hemodijaliza. Specifi&#x010D;na terapija (&#x201E;kokteli&#x201C;) prelazi okvire ovog teksta i nije dostupna ve&#x0107;ini ambulanta i bolnica. (<xref ref-type="bibr" rid="r105"><italic>105</italic></xref>&#x2013;<xref ref-type="bibr" rid="r109"><italic>109</italic></xref>) Pri sumnji na takvo stanje preporu&#x010D;uju se vrlo brza uspostava kontakta s lije&#x010D;nicima Referentnog centra za medicinsku genetiku i metaboli&#x010D;ke bolesti djece i upu&#x0107;ivanje djeteta na prikladno zbrinjavanje.</p>
</sec>
</sec>
<sec sec-type="other3">
<title>Zaklju&#x010D;ak</title>
<p>Novoro&#x0111;en&#x010D;e septi&#x010D;nog izgleda lije&#x010D;i se kao i ostala hitna stanja, prema strukturiranom pristupu ABCDE, radi pravodobne stabilizacije prije kona&#x010D;nog zbrinjavanja i definitivne dijagnoze. Primjerenim osiguravanjem di&#x0161;nog puta uz primjenu kisika i manualnu ili (prema potrebi) mehani&#x010D;ku ventilaciju te kontroliranu analgosedaciju (ako je indicirana), prevenira se kardiopulmonalno zatajenje uzrokovano respiratornom nedostatno&#x0161;&#x0107;u. Rana uspostava venskog puta, nadoknada cirkuliraju&#x0107;eg volumena uz korekciju acidobaznog statusa i elektrolitskog disbalansa iznimno su va&#x017E;ne za sprje&#x010D;avanje kardiocirkulatornog zatajenja u inicijalnoj fazi. Tako&#x0111;er, uzimanje hematolo&#x0161;ko-biokemijskih uzoraka i uzoraka za mikrobiolo&#x0161;ku obradu te zapo&#x010D;injanje dvojne antimikrobne terapije zlatni su standard radi rane prevencije razvoja septi&#x010D;kog &#x0161;oka. Dijagnosti&#x010D;ko-terapijska intervencija mora se upotpuniti kvalitetnim uzimanjem ciljanih anamnesti&#x010D;kih podataka i klini&#x010D;kim pregledom svih organskih sustava. Spasonosna je primjena prostaglandina radi odr&#x017E;avanja arterijskog duktusa, o&#x010D;uvanja sistemskog krvotoka i prevencije krvoto&#x010D;nog uru&#x0161;aja do kona&#x010D;nog ehokardiografskog isklju&#x010D;enja sr&#x010D;ane gre&#x0161;ke. U uznapredovaloj fazi bolesti katkad je nu&#x017E;na i kontrolirana inotropna potpora. Pri te&#x0161;kom op&#x0107;em stanju davanjem kortikosteroida mogu se lije&#x010D;iti &#x0161;ok neosjetljiv na primjenu inotropne terapije, ali i adrenalna kriza u sklopu kongenitalne adrenalne hiperplazije. Hipoglikemija i elektrolitski disbalans mogu se registrirati i promptno lije&#x010D;iti u sklopu kongenitalne adrenalne hiperplazije, ali i niza metaboli&#x010D;kih bolesti i stanja. Zasad nema sustavnih pregleda koji ujedinjuju dijagnosti&#x010D;ko-terapijski protokol, no aktualno ispisani prikaz mogao bi biti poticaj pedijatrijskim i neonatolo&#x0161;kim dru&#x0161;tvima da zajedni&#x010D;kim snagama donesu preporuke o zbrinjavanju bolesnika koji se prezentiraju klini&#x010D;kom slikom kasne novoro&#x0111;ena&#x010D;ke sepse.</p>
</sec>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="web">Nemsadze K. Early Detection and Prevention of Neonatal Sepsis. U: Resch B. (ur.). Neonatal Bacterial Infection. InTech; 2013. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.intechopen.com/books/neonatal-bacterial-infection/early-detection-and-prevention-of-neonatal-sepsis">https://www.intechopen.com/books/neonatal-bacterial-infection/early-detection-and-prevention-of-neonatal-sepsis</ext-link>. Pristupljeno: 10. 6. 2016.</mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>SY</given-names></name><name><surname>Sheiner</surname><given-names>E</given-names></name><name><surname>Zmora</surname><given-names>E</given-names></name><name><surname>Vardi</surname><given-names>H</given-names></name><name><surname>Shoham-Vardi</surname><given-names>I</given-names></name><name><surname>Mazor</surname><given-names>M</given-names></name></person-group>. <article-title>Risk factors for early neonatal sepsis.</article-title> <source>Arch Gynecol Obstet</source>. <year>2006</year>;<volume>274</volume>(<issue>4</issue>):<fpage>198</fpage>&#x2013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1007/s00404-006-0135-1</pub-id><pub-id pub-id-type="pmid">16491366</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="book">Sass L, Karlowitz MG. Healthcare-associated infections in the Neonate. U: Long SS, Prober CG, Fischer M (ur.). Principles and Practice of Pediatric Infectious Diseases. 5. izd. Philadelphia: Elsevier; 2018, str. 2769&#x2013;76.</mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefanovic</surname><given-names>IM</given-names></name></person-group>. <article-title>Neonatal sepsis.</article-title> <source>Biochem Med (Zagreb)</source>. <year>2011</year>;<volume>21</volume>(<issue>3</issue>):<fpage>276</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.11613/BM.2011.037</pub-id><pub-id pub-id-type="pmid">22420241</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="book">Puopolo KM. Bacterial and Fungal Infections. U: Cloherty JP, Eichenwald EC, Stark AR (ur.). Manual of Neonatal Care. 6. izd. Philadelphia: Wolters Kluwer, Lippincott Williams &amp; Wilkins; 2010, str. 274&#x2013;300.</mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="book">Gomella TL, Eyal FG, Zenk KE. (ur.). Infectious diseases, Neonatal sepsis. U: Neonatology Clinical Manual. 7. izd. New York: Lange Medical Books/McGraw-Hill Medical Publishing Division; 2014, str. 434&#x2013;41.</mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="book">Stoll BJ. Infection in the neonatal infant. U: Kliegman RM, Stanton BMD, St. Geme J, et al. (ur.). Nelson Textbook of Pediatrics. 19. izd. Philadelphia: Elsevier Saunders; 2016, str. 629&#x2013;48.</mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="book">Sinha S, Miall L, Jardine L. (ur.). Infection in the newborn. U: Essential Neonatal Medicine. 6. izd. New York: Wiley Blackwell; 2018, str. 121&#x2013;36.</mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="web">Edwards MS. Clinical features, evaluation, and diagnosis of sepsis in term and late preterm infants. UpToDate; 2019. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uptodate.com/contents/clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants?search=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and%20late-preterm-infants&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1">https://www.uptodate.com/contents/clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and-late-preterm-infants?search=clinical-features-evaluation-and-diagnosis-of-sepsis-in-term-and%20late-preterm-infants&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1</ext-link>. Pristupljeno: 27. 5. 2019.</mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="web">Edwards MS. Management and outcome of sepsis in term and late preterm infants. UpToDate; 2019. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants">https://www.uptodate.com/contents/management-and-outcome-of-sepsis-in-term-and-late-preterm-infants</ext-link>. Pristupljeno: 27. 5. 2019.</mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="web">Anderson-Berry AL, Bellig LL, Ohning BL. Neonatal sepsis. Medscape; 2015. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://emedicine.medscape.com/article/978352-overview">https://emedicine.medscape.com/article/978352-overview</ext-link>. Pristupljeno: 16. 6. 2016.</mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="book">Me&#x0161;trovi&#x0107; J. Novoro&#x0111;ena&#x010D;ke infekcije: novoro&#x0111;ena&#x010D;ka sepsa. U: Ivan&#x010D;evi&#x0107; &#x017D; (ur.). MSD Pedijatrija. Priru&#x010D;nik dijagnostike i terapije. Split: Placebo; 2014, str 2333&#x2013;8.</mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="other">Benjak V. Novoro&#x0111;en&#x010D;e septi&#x010D;nog izgleda. U: Me&#x0161;trovi&#x0107; J, et al. (ur.). Hitna stanja u pedijatriji. Zagreb: Medicinska naklada; 2011, str. 316&#x2013;49.</mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="web">Victorian Agency for Health Information. Sepsis in neonate. Victorian Agency for Health Information; 2014. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bettersafercare.vic.gov.au/resources/clinical-guidance/maternity-and-newborn-clinical-network/sepsis-in-neonates">https://bettersafercare.vic.gov.au/resources/clinical-guidance/maternity-and-newborn-clinical-network/sepsis-in-neonates</ext-link>. Pristupljeno: 7. 6. 2016.</mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silveira</surname><given-names>RC</given-names></name><name><surname>Giacomini</surname><given-names>C</given-names></name><name><surname>Soibelmann Procianoy</surname><given-names>R</given-names></name></person-group>. <article-title>Neonatal sepsis and septic shock: concepts update and review.</article-title> <source>Rev Bras Ter Intensiva</source>. <year>2010</year>;<volume>22</volume>(<issue>3</issue>):<fpage>280</fpage>&#x2013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">25302436</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ro&#x017E;mani&#x0107;</surname><given-names>V</given-names></name><name><surname>Lah-Tomuli&#x0107;</surname><given-names>K</given-names></name><name><surname>Gazdik</surname><given-names>M</given-names></name><name><surname>Ahel</surname><given-names>V</given-names></name></person-group>. <article-title>Sepsa i meningitis u novoro&#x0111;en&#x010D;eta.</article-title> <source>Paediatr Croat</source>. <year>2004</year>;<volume>48</volume> <supplement>Supl. 1</supplement>:<fpage>94</fpage>&#x2013;<lpage>100</lpage>.</mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="web">Satenahalli V. Neonatal sepsis in Slideshare Education. Health and Medicine; 2016. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.slideshare.net/virajsathenahalli/neonatal-sepsis-29904147">https://www.slideshare.net/virajsathenahalli/neonatal-sepsis-29904147</ext-link>. Pristupljeno: 8. 8. 2016.</mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="web">Adler LC, DiMaggio J, Zieve D, Conaway B. (ur.). Neonatal sepsis. U.S. National Library of Medicine. MedlinePlus; 2016. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://medlineplus.gov/ency/article/007303.htm">https://medlineplus.gov/ency/article/007303.htm</ext-link>. Pristupljeno: 11. 8. 2016.</mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Committee on Infectious Diseases</collab></person-group>. <article-title>Committee on Fetus and Newborn, Baker CJ, Byington CL, Polin RA. Policy Statement &#x2013; Recommendations for the Prevention of Perinatal Group B Streptococcal (GBS) disease.</article-title> <source>Pediatrics</source>. <year>2011</year>;<volume>128</volume>(<issue>3</issue>):<fpage>611</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">21807694</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>J</given-names></name><name><surname>Dimand</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Duenas</surname><given-names>GV</given-names></name><name><surname>Bennet</surname><given-names>MV</given-names></name><name><surname>Gould</surname><given-names>JB</given-names></name></person-group>. <article-title>Neonatal Intensive Care Unit Antibiotic Use.</article-title> <source>Pediatrics</source>. <year>2015</year>;<volume>135</volume>(<issue>5</issue>):<fpage>826</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-3409</pub-id><pub-id pub-id-type="pmid">25896845</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="other">Kimberlin DW, Brady MT, Jackson MA, Long SS (ur.). Respiratory Syncytial Infections. U: Red Book: Report of the Committee on Infectious Diseases. 31. izd. Illinois: American Academy of Pediatrics; 2018&#x2013;2021, str. 682&#x2013;92.</mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="other">Kimberlin DW, Brady MT, Jackson MA, Long SS (ur.). Group B Streptococcal Infections. U: Red Book: Report of the Committee on Infectious Diseases. 31. izd. Illinois: American Academy of Pediatrics; 2018&#x2013;2021, str. 762&#x2013;8.</mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Speer</surname><given-names>CP</given-names></name></person-group>. <article-title>Late-onset neonatal sepsis: recent developments.</article-title> <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2015</year>;<volume>100</volume>:<fpage>F257</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2014-306213</pub-id><pub-id pub-id-type="pmid">25425653</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="web">Fuchs A, Bielicki A, Mathur S, Sharland M, Van den Anker JN. Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update. WHO Review; 2016. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/selection_medicines/committees/expert/21/applications/s6_paed_antibiotics_appendix4_sepsis.pdf">https://www.who.int/selection_medicines/committees/expert/21/applications/s6_paed_antibiotics_appendix4_sepsis.pdf</ext-link>. Pristupljeno: 5. 11. 2018.</mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="book">Meissner HC. Bronchiolitis. U: Long SS, Prober CG, Fischer M (ur.). Principles and Practice of Pediatric Infectious Diseases. 5. izd. Philadelphia: Elsevier; 2018, str. 1212&#x2013;23.</mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debock</surname><given-names>I</given-names></name><name><surname>Flamand</surname><given-names>V</given-names></name></person-group>. <article-title>Unbalanced neonatal CD4<sup>+</sup> T-cell immunity.</article-title> <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>393</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00393</pub-id><pub-id pub-id-type="pmid">25221551</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adib</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Procalcitonin: A Reliable Marker for the Diagnosis of Neonatal Sepsis.</article-title> <source>Iran J Basic Med Sci</source>. <year>2012</year>;<volume>15</volume>(<issue>2</issue>):<fpage>777</fpage>&#x2013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">23493845</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontrelli</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Accuracy of serum procalcitonin for the diagnosis of sepsis in neonates and children with systemic inflammatory syndrome: a meta-analysis.</article-title> <source>BMC Infect Dis</source>. <year>2017</year>;<volume>17</volume>:<fpage>302</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-017-2396-7</pub-id><pub-id pub-id-type="pmid">28438138</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Maharoof</surname><given-names>MK</given-names></name><name><surname>Niyaz</surname><given-names>M</given-names></name></person-group>. <article-title>Role of procalcitonin in early diagnosis of neonatal sepsis.</article-title> <source>Int J Contemp Pediatr</source>. <year>2017</year>;<volume>4</volume>(<issue>2</issue>):<fpage>383</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.18203/2349-3291.ijcp20170477</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhodes</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Survinig Sepsis Campaign: Intenational Guidelines for Management of Sepsis and Septic Shock: 2016.</article-title> <source>Crit Care Med</source>. <year>2017</year>;<volume>45</volume>(<issue>3</issue>):<fpage>486</fpage>&#x2013;<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000002255</pub-id><pub-id pub-id-type="pmid">28098591</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>MM</given-names></name><name><surname>Evans</surname><given-names>LE</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name></person-group>. <article-title>The Surviving Sepsis Campaign Bundle: 2018 Update.</article-title> <source>Crit Care Med</source>. <year>2018</year>;<volume>46</volume>(<issue>6</issue>):<fpage>997</fpage>&#x2013;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000003119</pub-id><pub-id pub-id-type="pmid">29767636</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T</given-names></name></person-group>. <article-title>Update on Pediatric Sepsis: a review.</article-title> <source>J Intensive Care</source>. <year>2017</year>;<volume>5</volume>:<fpage>47</fpage>. <pub-id pub-id-type="doi">10.1186/s40560-017-0240-1</pub-id><pub-id pub-id-type="pmid">28729906</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malbrain</surname><given-names>MLNG</given-names></name><name><surname>Van Regenmortel</surname><given-names>N</given-names></name><name><surname>Saugel</surname><given-names>B</given-names></name><etal/></person-group> <article-title>Principles of fluid management and stepwards in septic shock: it is time to consider the four D&#x2019;s and the four phases of fluid therapy.</article-title> <source>Ann Intensive Care</source>. <year>2018</year>;<volume>8</volume>:<fpage>66</fpage>. <pub-id pub-id-type="doi">10.1186/s13613-018-0402-x</pub-id><pub-id pub-id-type="pmid">29789983</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avni</surname><given-names>T</given-names></name><name><surname>Larod</surname><given-names>A</given-names></name><name><surname>Lev</surname><given-names>S</given-names></name><name><surname>Leibovici</surname><given-names>L</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name><name><surname>Grossman</surname><given-names>A</given-names></name></person-group>. <article-title>Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.</article-title> <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>8</issue>):<elocation-id>e0129305</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0129305</pub-id><pub-id pub-id-type="pmid">26237037</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="other">Pollard S, Edwin SB, Alaniz C. Vasopressor and Inotropic Management Of Patients With Septic Shock. Pharm and Therap 2015;40(7):438&#x2013;42, 449&#x2013;50.</mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lampin</surname><given-names>ME</given-names></name><etal/></person-group> <article-title>Noradrenaline use for septic shock in children: doses, routes of administration and complications.</article-title> <source>Acta Paediatr</source>. <year>2012</year>;<volume>101</volume>(<issue>9</issue>):<fpage>e426</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.2012.02725.x</pub-id><pub-id pub-id-type="pmid">22568565</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>AM</given-names></name><etal/></person-group> <article-title>Dopamine increases mortality in pediatric septic shock: Double-Blind Prospective Randomized Controlled Trial of Dopamine Versus Epinephrine as First Line Vasoactive Drugs in Pediatric Septic Shock.</article-title> <source>Crit Care Med</source>. <year>2015</year>;<volume>43</volume>:<fpage>2292</fpage>&#x2013;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000001260</pub-id><pub-id pub-id-type="pmid">26323041</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruos</surname><given-names>JL</given-names></name><name><surname>McPherson</surname><given-names>C</given-names></name><name><surname>Dinardo</surname><given-names>J</given-names></name></person-group>. <article-title>Inotrope and Vasopressor Support in Neonates.</article-title> <source>Neoreviews</source>. <year>2015</year>;<volume>16</volume>(<issue>6</issue>):<fpage>e351</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1542/neo.16-6-e351</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Houwink</surname><given-names>AP</given-names></name><name><surname>Rijkenberg</surname><given-names>S</given-names></name><name><surname>Bosman</surname><given-names>RJ</given-names></name><name><surname>van der Voort</surname><given-names>PH</given-names></name></person-group>. <article-title>The association between lactate, mean arterial pressure, central venous oxygen saturation and peripheral temperature and mortality in severe sepsis: a retrospective cohort analysis.</article-title> <source>Crit Care</source>. <year>2016</year>;<volume>20</volume>:<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-016-1243-3</pub-id><pub-id pub-id-type="pmid">26968689</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maconochiea</surname><given-names>IK</given-names></name><name><surname>Binghamb</surname><given-names>R</given-names></name><name><surname>Eichc</surname><given-names>C</given-names></name><etal/></person-group> <article-title><italic>Paediatric life support section Collaborators.</italic> European Resuscitation Council Guidelines for Resuscitation 2015. Paediatric life support.</article-title> <source>Resuscitation</source>. <year>2015</year>;<volume>95</volume>:<fpage>223</fpage>&#x2013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1016/j.resuscitation.2015.07.028</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="book">Samuels M, Wieteska S. (ur.). The child in shock. U: Advanced Paediatric Life Support: The Practical Approach. 5. izd. BMJ Publishing Group. New Jersey: Wiley Blackwell; 2014., str. 120&#x2013;32.</mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>Y</given-names></name><name><surname>Katheria</surname><given-names>AC</given-names></name><name><surname>Vora</surname><given-names>F</given-names></name></person-group>. <article-title>Advances in Diagnosis and Management of Hemodynamic Instability in Neonatal Shock.</article-title> <source>Front Pediatr</source>. <year>2018</year>;<volume>6</volume>:<fpage>2</fpage>. <pub-id pub-id-type="doi">10.3389/fped.2018.00002</pub-id><pub-id pub-id-type="pmid">29404312</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pizarro</surname><given-names>CF</given-names></name><name><surname>Troster</surname><given-names>EJ</given-names></name><name><surname>Damiani</surname><given-names>D</given-names></name><name><surname>Carcillo</surname><given-names>JA</given-names></name></person-group>. <article-title>Absolute and relative adrenal insufficiency in children with septic shock.</article-title> <source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>(<issue>4</issue>):<fpage>855</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/01.CCM.0000159854.23324.84</pub-id><pub-id pub-id-type="pmid">15818116</pub-id></mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarthi</surname><given-names>M</given-names></name><name><surname>Lodha</surname><given-names>R</given-names></name><name><surname>Vivekanandhan</surname><given-names>S</given-names></name><name><surname>Arora</surname><given-names>NK</given-names></name></person-group>. <article-title>Adrenal status in children with septic shock using low dose stimulation test.</article-title> <source>Pediatr Crit Care Med</source>. <year>2007</year>;<volume>8</volume>(<issue>1</issue>):<fpage>23</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/01.pcc.0000256622.63135.90</pub-id><pub-id pub-id-type="pmid">17251878</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralston</surname><given-names>SL</given-names></name><etal/></person-group> <article-title>Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.</article-title> <source>Pediatrics</source>. <year>2014</year>;<volume>134</volume>(<issue>5</issue>):<fpage>e1474</fpage>&#x2013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2014-2742</pub-id><pub-id pub-id-type="pmid">25349312</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JA</given-names></name><name><surname>Madikians</surname><given-names>A</given-names></name></person-group>. <article-title>From bronchiolitis guideline to practice: A critical care perspective.</article-title> <source>World J Crit Care Med</source>. <year>2015</year>;<volume>4</volume>(<issue>3</issue>):<fpage>152</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5492/wjccm.v4.i3.152</pub-id><pub-id pub-id-type="pmid">26261767</pub-id></mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>J</given-names></name><etal/></person-group> <article-title>Hypertonic Saline for the Treatment of Bronchiolitis in Infants and Young Children: A Critical Review of the Literature.</article-title> <source>J Pediatr Pharmacol Ther</source>. <year>2016</year>;<volume>21</volume>(<issue>1</issue>):<fpage>7</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.5863/1551-6776-21.1.7</pub-id><pub-id pub-id-type="pmid">26997926</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panda</surname><given-names>S</given-names></name><name><surname>Mohakud</surname><given-names>NK</given-names></name><name><surname>Pena</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Human metapneumovirus: review of an important respiratory pathogen.</article-title> <source>Int J Infect Dis</source>. <year>2014</year>;<volume>25</volume>:<fpage>45</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.03.1394</pub-id><pub-id pub-id-type="pmid">24841931</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejanovi&#x0107;</surname><given-names>S</given-names></name><name><surname>Te&#x0161;ovi&#x0107;</surname><given-names>G</given-names></name></person-group>. <article-title>Hripavac.</article-title> <source>Paediatr Croat</source>. <year>2014</year>;<volume>8</volume> <supplement>Supl. 1</supplement>:<fpage>23</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Te&#x0161;ovi&#x0107;</surname><given-names>G</given-names></name></person-group>. <article-title>Infekcije respiratornog sustava u djece &#x2013; novosti u primjeni azitromicina.</article-title> <source>Medicus</source>. <year>2008</year>;<volume>7</volume>(<issue>2</issue>):<fpage>21</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="other">Kimberlin DW, Brady MT, Jackson MA, Long SS (ur.). Pertusis (Whooping Cough). U: Red Book: Report of the Committee on Infectious Diseases. 31. izd. Illinois: American Academy of Pediatrics; 2018&#x2013;2021, str. 620&#x2013;34.</mixed-citation></ref>
<ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>LT</given-names></name><name><surname>Ho</surname><given-names>MY</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name></person-group>. <article-title>A neonate with Bordetella pertusis pneumonia presenting with cough and cyanosis.</article-title> <source>J Pediatr Resp Dis</source>. <year>2013</year>;<volume>9</volume>:<fpage>87</fpage>&#x2013;<lpage>90</lpage>.</mixed-citation></ref>
<ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0141;oniewska</surname><given-names>B</given-names></name><name><surname>Kordek</surname><given-names>A</given-names></name><name><surname>Michalczyk</surname><given-names>B</given-names></name><name><surname>Blazejczak</surname><given-names>A</given-names></name><name><surname>Ciechanowska</surname><given-names>B</given-names></name></person-group>. <article-title>A case of undiagnosed Bordetella pertusis infection in a neonate.</article-title> <source>Pomeranian J Life Sci</source>. <year>2016</year>;<volume>62</volume>(<issue>2</issue>):<fpage>63</fpage>&#x2013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">29537239</pub-id></mixed-citation></ref>
<ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirthalingam</surname><given-names>G</given-names></name></person-group>. <article-title>Strategies to control pertussis in infant.</article-title> <source>Arch Dis Child</source>. <year>2013</year>;<volume>98</volume>:<fpage>552</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2012-302968</pub-id><pub-id pub-id-type="pmid">23698594</pub-id></mixed-citation></ref>
<ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothari</surname><given-names>DS</given-names></name><name><surname>Skinner</surname><given-names>JR</given-names></name></person-group>. <article-title>Neonatal tachycardias: an update.</article-title> <source>Arch Dis Child Fetal Neonatal Ed</source>. <year>2006</year>;<volume>91</volume>:<fpage>F136</fpage>&#x2013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2004.049049</pub-id><pub-id pub-id-type="pmid">16492952</pub-id></mixed-citation></ref>
<ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>CK</given-names></name></person-group>. <article-title>Paroxyzmal Supraventricular Tahcycardia in Neonates.</article-title> <source>Int J Pharma Bio Sci</source>. <year>2012</year>;<volume>3</volume>(<issue>2</issue>):<fpage>140</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="r57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salerno</surname><given-names>JC</given-names></name><name><surname>Seslar</surname><given-names>SP</given-names></name></person-group>. <article-title>Supraventricular Tachycardia.</article-title> <source>Arch Pediatr Adolesc Med</source>. <year>2009</year>;<volume>163</volume>(<issue>3</issue>):<fpage>268</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1001/archpediatrics.2008.547</pub-id><pub-id pub-id-type="pmid">19255396</pub-id></mixed-citation></ref>
<ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killen</surname><given-names>SAS</given-names></name><name><surname>Fish</surname><given-names>FA</given-names></name></person-group>. <article-title>Fetal and Neonatal Arrhythmias.</article-title> <source>NeoRev</source>. <year>2008</year>;<volume>9</volume>(<issue>6</issue>):<fpage>e242</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1542/neo.9-6-e242</pub-id></mixed-citation></ref>
<ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>JE</given-names></name></person-group>. <article-title>Neonatal arrhythmias: diagnosis, treatment and clinical outcome.</article-title> <source>Korean J Pediatr</source>. <year>2017</year>;<volume>60</volume>(<issue>11</issue>):<fpage>344</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.3345/kjp.2017.60.11.344</pub-id><pub-id pub-id-type="pmid">29234357</pub-id></mixed-citation></ref>
<ref id="r60"><label>60</label><mixed-citation publication-type="book">Park MK. Cardiac Arrhythmias: Supraventricular Tachycardia. U: Park MK (ur.). Pediatric Cardiology for Practitioners. 5. izd. Philadelphia: Mosby Elsevier; 2008, str. 417&#x2013;29.</mixed-citation></ref>
<ref id="r61"><label>61</label><mixed-citation publication-type="book">Zimmerman F. Supraventricular Tachycardia. U: Koenig P, Hijazi ZM, Zimmermann F (ur.). Essential Pediatric Cardiology. Chicago: McGraw-Hill; 2004, str 301&#x2013;11, 393&#x2013;7.</mixed-citation></ref>
<ref id="r62"><label>62</label><mixed-citation publication-type="book">Samuels M, Wieteska S. (ur.). The child with an abnormanl pulse rate or rhythm. U: Advanced Paediatric Life Support: The Practical Approach. 5. izd. BMJ Publishing Group. New Jersey: Wiley Blackwell; 2014, str. 107&#x2013;15.</mixed-citation></ref>
<ref id="r63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katritsis</surname><given-names>DG</given-names></name><name><surname>Boriani</surname><given-names>G</given-names></name><name><surname>Cosio</surname><given-names>FG</given-names></name><etal/></person-group> <article-title>European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci&#x00F3;n Cardiaca y Electrofisiologia (SOLAECE).</article-title> <source>Europace</source>. <year>2017</year>;<volume>19</volume>(<issue>3</issue>):<fpage>465</fpage>&#x2013;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1093/europace/euw301</pub-id><pub-id pub-id-type="pmid">27856540</pub-id></mixed-citation></ref>
<ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugada</surname><given-names>J</given-names></name><name><surname>Blom</surname><given-names>N</given-names></name><name><surname>Sarquella-Brugada</surname><given-names>G</given-names></name><etal/></person-group> <article-title><italic>European Heart Rhythm Association; Association for European Paediatric and Congenital Cardiology.</italic> Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement.</article-title> <source>Europace</source>. <year>2013</year>;<volume>15</volume>(<issue>9</issue>):<fpage>1337</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1093/europace/eut082</pub-id><pub-id pub-id-type="pmid">23851511</pub-id></mixed-citation></ref>
<ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backhoff</surname><given-names>D</given-names></name></person-group>. <article-title>Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Infants and Toddlers &#x2264; 15 kg.</article-title> <source>Pediatr Cardiol</source>. <year>2016</year>;<volume>37</volume>(<issue>5</issue>):<fpage>892</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-016-1365-z</pub-id><pub-id pub-id-type="pmid">26961570</pub-id></mixed-citation></ref>
<ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozaki</surname><given-names>N</given-names></name><etal/></person-group> <article-title>Safety and Efficacy of Radiofrequency Catheter Ablation for Tachyarrhythmia in Children Weighing Less Than 10 kg.</article-title> <source>Pediatr Cardiol</source>. <year>2018</year>;<volume>39</volume>(<issue>2</issue>):<fpage>384</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-017-1766-7</pub-id><pub-id pub-id-type="pmid">29119214</pub-id></mixed-citation></ref>
<ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puljevi&#x0107;</surname><given-names>D</given-names></name></person-group>. <article-title>Elektrofiziolo&#x0161;ko lije&#x010D;enje aritmija u djece.</article-title> <source>Paediatr Croat</source>. <year>2017</year>;<volume>61</volume> <supplement>Supl. 1</supplement>:<fpage>107</fpage>&#x2013;<lpage>11</lpage>.</mixed-citation></ref>
<ref id="r68"><label>68</label><mixed-citation publication-type="book">Sinha S, Miall L, Jardine L. (ur.). Cardiovascular disorders. U: Essential Neonatal Medicine. 6. izd. New York: Wiley Blackwell; 2018, str. 194&#x2013;210.</mixed-citation></ref>
<ref id="r69"><label>69</label><mixed-citation publication-type="web">Dilber D. Distribucija priro&#x0111;enih sr&#x010D;anih gre&#x0161;aka u Hrvatskoj, analiza rizi&#x010D;nih &#x010D;imbenika i ishoda lije&#x010D;enja. Doktorska disertacija. Sveu&#x010D;ili&#x0161;te u Zagrebu; 2010. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://medlib.mef.hr/867">http://medlib.mef.hr/867</ext-link>.</mixed-citation></ref>
<ref id="r70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ro&#x017E;mani&#x0107;</surname><given-names>V</given-names></name></person-group>. <article-title>Cijanoza u novoro&#x0111;ena&#x010D;koj dobi.</article-title> <source>Paediatr Croat</source>. <year>2009</year>;<volume>53</volume> <supplement>Supl. 1</supplement>:<fpage>51</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="r71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>D</given-names></name></person-group>. <article-title>Patophysiology of Congenital Heart Diseases.</article-title> <source>Ann Card Anaesth</source>. <year>2007</year>;<volume>10</volume>:<fpage>19</fpage>&#x2013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.4103/0971-9784.37920</pub-id><pub-id pub-id-type="pmid">17455404</pub-id></mixed-citation></ref>
<ref id="r72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>EB</given-names></name></person-group>. <article-title>Pathogenetic mechanisms of congenital cardiovascular malformationes revisited.</article-title> <source>Semin Perinatol</source>. <year>1996</year>;<volume>20</volume>:<fpage>465</fpage>&#x2013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S0146-0005(96)80062-0</pub-id><pub-id pub-id-type="pmid">9090774</pub-id></mixed-citation></ref>
<ref id="r73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahel</surname><given-names>V</given-names></name><name><surname>&#x010C;a&#x010D;e</surname><given-names>N</given-names></name><name><surname>Dessandro</surname><given-names>S</given-names></name><name><surname>Ro&#x017E;mani&#x0107;</surname><given-names>V</given-names></name></person-group>. <article-title>Uloga rane dijagnostike i lije&#x010D;enja priro&#x0111;enih sr&#x010D;anih gre&#x0161;aka.</article-title> <source>Paediatr Croat</source>. <year>2004</year>;<volume>48</volume> <supplement>Supl 1</supplement>:<fpage>111</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="r74"><label>74</label><mixed-citation publication-type="book">Samuels M, Wieteska S. (ur.). Approach to the infant with a duct-dependent congenital heart disease. U: Advanced Paediatric Life Support: The Practical Approach. 5. izd. BMJ Publishing Group. New Jersey: Wiley Blackwell; 2014, str. 135&#x2013;7.</mixed-citation></ref>
<ref id="r75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silove</surname><given-names>ED</given-names></name></person-group>. <article-title>Evaluation of oral and low dose intravenous prostaglandin E<sub>2</sub> in management of ductus dependent congenital heart disease.</article-title> <source>Arch Dis Child</source>. <year>1985</year>;<volume>60</volume>(<issue>11</issue>):<fpage>1025</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1136/adc.60.11.1025</pub-id><pub-id pub-id-type="pmid">3865636</pub-id></mixed-citation></ref>
<ref id="r76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>DS</given-names></name><etal/></person-group> <article-title>Aminophylline for the Prevention of Apnea During Prostaglandin E<sub>1</sub> Infusion.</article-title> <source>Pediatrics</source>. <year>2003</year>;<volume>112</volume>(<issue>1 Pt 1</issue>):<fpage>e27</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1542/peds.112.1.e27</pub-id><pub-id pub-id-type="pmid">12837902</pub-id></mixed-citation></ref>
<ref id="r77"><label>77</label><mixed-citation publication-type="book">Boshoff DE, Gewillig MH. Creating an Interatrial Communication. U: Butera G, Chessa M, Eicken A, Thompson J (ur.). Cardiac Catheterization for Congenital Heart Disease From Fetal Life to Adulthood. Cham: Springer; 2015, str. 571&#x2013;89.</mixed-citation></ref>
<ref id="r78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0160;ari&#x0107;</surname><given-names>D</given-names></name></person-group>. <article-title>Noviji pristup lije&#x010D;enju zatajenja srca djece.</article-title> <source>Paediatr Croat</source>. <year>2009</year>;<volume>53</volume> <supplement>Supl. 1</supplement>:<fpage>76</fpage>&#x2013;<lpage>81</lpage>.</mixed-citation></ref>
<ref id="r79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaddy</surname><given-names>RE</given-names></name><name><surname>George</surname><given-names>AT</given-names></name><name><surname>Jaecklin</surname><given-names>T</given-names></name><etal/></person-group> <article-title>Systematic Literature Rewiev on the Incidence and Prevalence of Heart Failure in Children and Adolescents.</article-title> <source>Pediatr Cardiol</source>. <year>2018</year>;<volume>39</volume>(<issue>3</issue>):<fpage>415</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1007/s00246-017-1787-2</pub-id><pub-id pub-id-type="pmid">29260263</pub-id></mixed-citation></ref>
<ref id="r80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brissaud</surname><given-names>O</given-names></name><name><surname>Botte</surname><given-names>A</given-names></name><name><surname>Cambonie</surname><given-names>G</given-names></name><etal/></person-group> <article-title>Experts&#x2019; recommendations for the management of cardiogenic shock in children.</article-title> <source>Ann Intensive Care</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>14</fpage>. <pub-id pub-id-type="doi">10.1186/s13613-016-0111-2</pub-id><pub-id pub-id-type="pmid">26879087</pub-id></mixed-citation></ref>
<ref id="r81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masarone</surname><given-names>D</given-names></name><name><surname>Valente</surname><given-names>F</given-names></name><name><surname>Rubino</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Pediatric Heart Failure: A Practical Guide to Diagnosis and Management.</article-title> <source>Pediatr Neonatol</source>. <year>2017</year>;<volume>58</volume>(<issue>4</issue>):<fpage>303</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.pedneo.2017.01.001</pub-id><pub-id pub-id-type="pmid">28279666</pub-id></mixed-citation></ref>
<ref id="r82"><label>82</label><mixed-citation publication-type="web">Bistola V, Chioncel O. Inotropes in acute heart failure. Continuing Cardiology Education 2017;3(3):107&#x2013;16. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://onlinelibrary.wiley.com/doi/full/10.1002/cce2.59">https://onlinelibrary.wiley.com/doi/full/10.1002/cce2.59</ext-link>, Pristupljeno: 10. 6. 2018.</mixed-citation></ref>
<ref id="r83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luli&#x0107; Jurjevi&#x0107;</surname><given-names>R</given-names></name><name><surname>Lukanovi&#x0107;</surname><given-names>T</given-names></name><name><surname>Raki&#x0107;</surname><given-names>M</given-names></name></person-group>. <article-title>Fetalna ehokardiografija u ranom otkrivanju priro&#x0111;enih sr&#x010D;anih gre&#x0161;aka.</article-title> <source>Paediatr Croat</source>. <year>2017</year>;<volume>61</volume> <supplement>Supl. 1</supplement>:<fpage>112</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="r84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levicki</surname><given-names>R</given-names></name><name><surname>Sovi&#x0107;</surname><given-names>S</given-names></name><name><surname>Mal&#x010D;i&#x0107;</surname><given-names>I</given-names></name></person-group>. <article-title>Indikacijske smjernice za fetalnu ehokardiografiju i njihov utjecaj na prenatalnu dijagnostiku sr&#x010D;ane bolesti.</article-title> <source>Lijec Vjesn</source>. <year>2017</year>;<volume>139</volume>:<fpage>150</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="r85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzoni</surname><given-names>P</given-names></name><name><surname>Martin</surname><given-names>GR</given-names></name><name><surname>Sanchez Luna</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Pulse oximetry screening for critical congenital heart defects: a European consensus statement.</article-title> <source>Lancet Child Adolesc Health</source>. <year>2017</year>;<volume>1</volume>(<issue>2</issue>):<fpage>88</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S2352-4642(17)30066-4</pub-id><pub-id pub-id-type="pmid">30169211</pub-id></mixed-citation></ref>
<ref id="r86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewer</surname><given-names>AK</given-names></name><name><surname>Martin</surname><given-names>GR</given-names></name></person-group>. <article-title>Newborn Pulse Oximetry Screening: Which Algorithm Is Best?</article-title> <source>Pediatrics</source>. <year>2016</year>;<volume>138</volume>(<issue>5</issue>):<elocation-id>e20161206</elocation-id>. <pub-id pub-id-type="doi">10.1542/peds.2016-1206</pub-id><pub-id pub-id-type="pmid">27940777</pub-id></mixed-citation></ref>
<ref id="r87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mawson</surname><given-names>IE</given-names></name><name><surname>Babu</surname><given-names>PL</given-names></name><name><surname>Simpson</surname><given-names>JM</given-names></name><name><surname>Fox</surname><given-names>GF</given-names></name></person-group>. <article-title>Pulse oximetry in newborns with antenatally diagnosed congenital heart disease.</article-title> <source>Eur J Pediatr</source>. <year>2018</year>;<volume>177</volume>(<issue>5</issue>):<fpage>683</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00431-018-3093-2</pub-id><pub-id pub-id-type="pmid">29404717</pub-id></mixed-citation></ref>
<ref id="r88"><label>88</label><mixed-citation publication-type="web">Oster M. Newborn screening for critical congenital heart disease using pulse oximetry. UpToDate; 2019. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.uptodate.com/contents/newborn-screening-for-critical-congenital-heart-disease-using-pulse-oximetry">https://www.uptodate.com/contents/newborn-screening-for-critical-congenital-heart-disease-using-pulse-oximetry</ext-link>. Pristupljeno: 27. 5. 2019.</mixed-citation></ref>
<ref id="r89"><label>89</label><mixed-citation publication-type="web">Centers for Disease Control and Prevention. Congenital Heart Defects (CHDs); 2018. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/ncbddd/heartdefects/hcp.html">https://www.cdc.gov/ncbddd/heartdefects/hcp.html</ext-link>. Pristupljeno: 14. 11. 2018.</mixed-citation></ref>
<ref id="r90"><label>90</label><mixed-citation publication-type="book">Sinha S, Miall L, Jardine L. (ur.). Endocrine and metabolic disorders. U: Essential Neonatal Medicine. 6. izd. New York: Wiley Blackwell; 2018, str. 268&#x2013;395.</mixed-citation></ref>
<ref id="r91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thornton</surname><given-names>PS</given-names></name><name><surname>Stanley</surname><given-names>CA</given-names></name><name><surname>De Leon</surname><given-names>DD</given-names></name><etal/></person-group> <article-title>Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglicemia in Neonates, Infants and Children.</article-title> <source>J Pediatr</source>. <year>2015</year>;<volume>167</volume>(<issue>2</issue>):<fpage>238</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2015.03.057</pub-id><pub-id pub-id-type="pmid">25957977</pub-id></mixed-citation></ref>
<ref id="r92"><label>92</label><mixed-citation publication-type="book">Hussain K, Dunne MJ. Hypoglycemia. U: Brook CGD, Brown RS (ur.). Handbook of Clinical Pediatric Endocrinology. 5. izd. Massachusetts Oxford Victoria: Blackwell Publishing; 2005, str. 474&#x2013;88.</mixed-citation></ref>
<ref id="r93"><label>93</label><mixed-citation publication-type="book">Samuels M, Wieteska S. (ur.). The child with a decreased conscious level. U: Advanced Paediatric Life Support: The Practical Approach. 5. izd. BMJ Publishing Group. New Jersey: Wiley Blackwell; 2014, str. 161.</mixed-citation></ref>
<ref id="r94"><label>94</label><mixed-citation publication-type="web">Wilson T. Congenital Adrenal Hyperplasia. Medscape; 2018. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://emedicine.medscape.com/article/919218-overview">https://emedicine.medscape.com/article/919218-overview</ext-link>. Pristupljeno: 5. 8. 2018.</mixed-citation></ref>
<ref id="r95"><label>95</label><mixed-citation publication-type="web">Speiser PW. Rare Disease Database. NORD National Organization for Rare Disorders; 2016. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rarediseases.org/rare-diseases/congenital-adrenal-hyperplasia/">https://rarediseases.org/rare-diseases/congenital-adrenal-hyperplasia/</ext-link>. Pristupljeno: 1. 10. 2016.</mixed-citation></ref>
<ref id="r96"><label>96</label><mixed-citation publication-type="web">McKusick VA, Hamosh A. Adrenal Hyperplasia, Congenital, due to 21-hydroxylase deficiency #201910. OMIM Entry; 2018. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.omim.org/entry/201910">http://www.omim.org/entry/201910</ext-link>. Pristupljeno: 1. 10. 2016.</mixed-citation></ref>
<ref id="r97"><label>97</label><mixed-citation publication-type="web">Boia M, Manea A, Mutica N, Micle I, Marginean O. Adrenogenital syndrome: positive diagnosis, evolution and prognosis. Journalul Pediatrului 2015;18(71&#x2013;72):41&#x2013;3. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.jurnalulpediatrului.ro/magazines/71-72.pdf">http://www.jurnalulpediatrului.ro/magazines/71-72.pdf</ext-link>. Pristupljeno: 1. 10. 2016.</mixed-citation></ref>
<ref id="r98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Section on Endocrinology and Committee on Genetics</collab></person-group>. <article-title>Technical Report: Congenital Adrenal Hyperplasia.</article-title> <source>Pediatrics</source>. <year>2000</year>;<volume>106</volume>(<issue>6</issue>):<fpage>1511</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1542/peds.106.6.1511</pub-id><pub-id pub-id-type="pmid">11099616</pub-id></mixed-citation></ref>
<ref id="r99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forest</surname><given-names>MG</given-names></name></person-group>. <article-title>Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</article-title> <source>Hum Reprod Update</source>. <year>2004</year>;<volume>10</volume>(<issue>6</issue>):<fpage>469</fpage>&#x2013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1093/humupd/dmh047</pub-id><pub-id pub-id-type="pmid">15514016</pub-id></mixed-citation></ref>
<ref id="r100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku&#x0161;ec</surname><given-names>V</given-names></name></person-group>. <article-title>Mjerenje hormona u kongenitalnoj adrenalnoj hiperplaziji &#x2013; dijagnostika i novoro&#x0111;ena&#x010D;ki probir.</article-title> <source>Paediatr Croat</source>. <year>2010</year>;<volume>54</volume> <supplement>Supl. 1</supplement>:<fpage>27</fpage>&#x2013;<lpage>33</lpage>.</mixed-citation></ref>
<ref id="r101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ille</surname><given-names>J</given-names></name></person-group>. <article-title>Prenatalna dijagnostika kongenitalne adrenalne hiperplazije zbog manjka enzima 21-hidroksilaze.</article-title> <source>Paediatr Croat</source>. <year>2010</year>;<volume>54</volume> <supplement>Supl. 1</supplement>:<fpage>44</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="r102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grubi&#x0107;</surname><given-names>Z</given-names></name></person-group>. <article-title>Molekularna dijagnostika kongenitalne adrenalne hiperplazije (KAH-a) zbog manjka 21-hidroksilaze.</article-title> <source>Paediatr Croat</source>. <year>2010</year>;<volume>54</volume> <supplement>Supl. 1</supplement>:<fpage>34</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="r103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0160;tingl</surname><given-names>K</given-names></name></person-group>. <article-title>Molekularna dijagnostika KAH-a zbog manjka 11-hidroksilaze i 17-hidroksilaze/17,20 liaze.</article-title> <source>Paediatr Croat</source>. <year>2010</year>;<volume>54</volume> <supplement>Supl. 1</supplement>:<fpage>37</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="r104"><label>104</label><mixed-citation publication-type="web">Saudubray JM, Desguerre I, Sedel F, Charpentier C. A Clinical Approach to Inherited Metabolic Diseases. Inborn Metabolic Diseases; 2019. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://eknygos.lsmuni.lt/springer/223/1%20Part/3-48.pdf">http://eknygos.lsmuni.lt/springer/223/1%20Part/3-48.pdf</ext-link>. Pristupljeno: 27. 5. 2019.</mixed-citation></ref>
<ref id="r105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Kabra</surname><given-names>M</given-names></name><name><surname>Deorari</surname><given-names>AK</given-names></name><name><surname>Paul</surname><given-names>VK</given-names></name></person-group>. <article-title>Approach to Inborn Errors of Metabolism Presenting in the Neonate.</article-title> <source>Indian J Pediatr</source>. <year>2008</year>;<volume>75</volume>(<issue>3</issue>):<fpage>271</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s12098-008-0058-x</pub-id><pub-id pub-id-type="pmid">18376097</pub-id></mixed-citation></ref>
<ref id="r106"><label>106</label><mixed-citation publication-type="other">Bari&#x0107; I. Hitna stanja zbog nasljednih metaboli&#x010D;kih bolesti. U: Me&#x0161;trovi&#x0107; J, et al. (ur.). Hitna stanja u pedijatriji. Zagreb: Medicinska naklada; 2011, str. 461&#x2013;75.</mixed-citation></ref>
<ref id="r107"><label>107</label><mixed-citation publication-type="web">Intensive Care Nursery House Staff Manual. Inborn errors of metabolism. UCSF Children&#x2019;s Hospital at UCSF Medical Center; 2016. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ucsfbenioffchildrens.org/pdf/manuals/53_Metabolism.pdf">https://www.ucsfbenioffchildrens.org/pdf/manuals/53_Metabolism.pdf</ext-link>. Pristupljeno: 13. 9. 2016.</mixed-citation></ref>
<ref id="r108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari&#x0107;</surname><given-names>I</given-names></name></person-group>. <article-title>Kako na vrijeme prepoznati i suzbiti nasljednu metaboli&#x010D;ku bolest u novoro&#x0111;en&#x010D;eta?</article-title> <source>Paediatr Croat</source>. <year>2011</year>;<volume>55</volume> <supplement>Supl. 1</supplement>:<fpage>167</fpage>&#x2013;<lpage>72</lpage>.</mixed-citation></ref>
<ref id="r109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari&#x0107;</surname><given-names>I</given-names></name></person-group>. <article-title>Akutno ugro&#x017E;eni bolesnici &#x2013; kako prepoznati i suzbiti nasljedni metaboli&#x010D;ki poreme&#x0107;aj?</article-title> <source>Paediatr Croat</source>. <year>2009</year>;<volume>53</volume> <supplement>Supl. 1</supplement>:<fpage>133</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="r110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari&#x0107;</surname><given-names>I</given-names></name></person-group>. <article-title>Osnovne metaboli&#x010D;ke pretrage: indikacije i evaluacija.</article-title> <source>Paediatr Croat</source>. <year>2004</year>;<volume>48</volume> <supplement>Supl. 1</supplement>:<fpage>89</fpage>&#x2013;<lpage>93</lpage>.</mixed-citation></ref>
<ref id="r111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari&#x0107;</surname><given-names>I</given-names></name></person-group>. <article-title>Racionalna dijagnostika nasljednih metaboli&#x010D;kih bolesti.</article-title> <source>Paediatr Croat</source>. <year>2004</year>;<volume>48</volume> <supplement>Supl. 1</supplement>:<fpage>155</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
</ref-list>
</back>
</article>
